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A B S T R A C T
Background
Traditionally inhaled treatment for asthma has been considered as preventer and reliever therapy. The combination of formoterol and
budesonide in a single inhaler introduces the possibility of using a single inhaler for both prevention and relief of symptoms (single
inhaler therapy).
Objectives
The aim of this review is to compare formoterol and corticosteroid in single inhaler for maintenance and relief of symptoms with
inhaled corticosteroids for maintenance and a separate reliever inhaler.
Search methods
We last searched the Cochrane Airways Group trials register in September 2008.
Selection criteria
Randomised controlled trials in adults and children with chronic asthma.
Data collection and analysis
Two review authors independently assessed studies for inclusion and extracted the characteristics and results of each study. Authors or
manufacturers were asked to supply unpublished data in relation to primary outcomes.
Main results
Five studies on 5,378 adults compared single inhaler therapy with current best practice, and did not show a significant reduction in
participants with exacerbations causing hospitalisation (Peto OR 0.59; 95% CI 0.24 to 1.45) or treated with oral steroids (OR 0.83;
95% CI 0.66 to 1.03). Three of these studies on 4281 adults did not show a significant reduction in time to first severe exacerbation
needing medical intervention (HR 0.96; 95% CI 0.85 to 1.07). These trials demonstrated a reduction in the mean total daily dose of
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inhaled corticosteroids with single inhaler therapy (mean reduction ranged from 107 to 267 micrograms/day, but the trial results were
not combined due to heterogeneity). The full results from four further studies on 4,600 adults comparing single inhaler therapy with
current best practice are awaited.
Three studies including 4,209 adults compared single inhaler therapy with higher dose budesonide maintenance and terbutaline for
symptom relief. No significant reduction was found with single inhaler therapy in the risk of patients suffering an asthma exacerbation
leading to hospitalisation (Peto OR 0.56; 95% CI 0.28 to 1.09), but fewer patients on single inhaler therapy needed a course of oral
corticosteroids (OR 0.54; 95% CI 0.45 to 0.64). These results translate into an eleven month number needed to treat of 14 (95%
CI 12 to 18), to prevent one patient being treated with oral corticosteroids for an exacerbation. The run-in for these studies involved
withdrawal of long-acting beta2-agonists, and patients were recruited who were symptomatic during run-in.
One study included children (N = 224), in which single inhaler therapy was compared to higher dose budesonide. There was a
significant reduction in participants who needed an increase in their inhaled steroids with single inhaler therapy, but there were only
two hospitalisations for asthma and no separate data on courses of oral corticosteroids. Less inhaled and oral corticosteroids were used
in the single inhaler therapy group and the annual height gain was also 1 cm greater in the single inhaler therapy group, [95% CI 0.3
to 1.7 cm].
There was no significant difference found in fatal or non-fatal serious adverse events for any of the comparisons.
Authors’ conclusions
Single inhaler therapy can reduce the risk of asthma exacerbations needing oral corticosteroids in comparisonwith fixeddosemaintenance
inhaled corticosteroids. Guidelines and common best practice suggest the addition of regular long-acting beta2-agonist to inhaled
corticosteroids for uncontrolled asthma, and single inhaler therapy has not been demonstrated to significantly reduce exacerbations in
comparison with current best practice, although results of five large trials are awaiting full publication. Single inhaler therapy is not
currently licensed for children under 18 years of age in the United Kingdom.
P L A I N L A N G U A G E S U M M A R Y
Combination of formoterol and budesonide as single inhaler therapy versus inhaled corticosteroid maintenance and a separate
reliever inhaler, or current best practice
A single combination inhaler containing formoterol and budesonide has been advocated for regular maintenance of asthma, with the
option to increase the dose if the asthma flares up. This is sometimes known as single inhaler therapy. Single inhaler therapy can reduce
the risk of asthma exacerbations needing oral corticosteroids in comparison with fixed dose maintenance inhaled corticosteroids. The
trials were in people with asthma who had their maintenance treatment reduced and became symptomatic. These results have not
yet been replicated in trials comparing single inhaler therapy with current best practice, and the results of five large trials are awaiting
publication. The place of this new approach to asthma management must remain somewhat uncertain until all the trials are fully
reported.
B A C K G R O U N D
Description of the condition
There is currently no universally accepted definition of the term
’asthma’. This is in part due to an overlap of symptoms with other
diseases such as chronic bronchitis, but is also due to the probable
existence of more than one underlying pathophysiological process.
There are, for example, wide variations in the age of onset, symp-
toms, triggers, association with allergic disease and the type of in-
flammatory cell infiltrate seen in patients diagnosed with asthma.
Patients will typically all have intermittent symptoms of cough,
wheeze and/or breathlessness. Underlying these symptoms there
is a process of variable, at least partially reversible airway obstruc-
tion, airway hyper responsiveness and (with the possible exception
of solely exercise-induced asthma) chronic inflammation.
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Description of the intervention
People with persistent asthma can use preventer therapy (usually
low dose inhaled corticosteroid (ICS)) to maintain symptom con-
trol, improve lung function and reduce emergency care require-
ment. However, when symptoms deteriorate reliever medication
in the form of short-acting beta-agonists such as salbutamol or
terbutaline, or formoterol (a fast-acting but longer lasting formula-
tion) can be used on an ’as needed’ basis (BTS/SIGN 2008). Since
most exacerbations have an onset over several days (Tattersfield
1999) there is potential for the person with asthma to increase
both budesonide and formoterol at an early stage in response to
increased symptoms of asthma. The pharmacological properties
of another long-acting beta2-agonist (LABA), salmeterol, result in
slower onset of bronchodilation (Palmqvist 2001), and it is not
licensed for use on an ’as needed’ basis. The inclusion of ICS in a
reliever inhaler for use during episodes of loss of control requires
monitoring and assessment of overall ICS dose (BTS/SIGN2008).
How the intervention might work
The combination of ICS and LABA in one inhaler is an ef-
fective way of delivering maintenance anti-inflammatory and
bronchodilator therapy in chronic asthma (Greenstone 2005; Ni
Chroinin 2005). The anti-inflammatory properties of the ICS
and the bronchodilatory effect of the LABA play complementary
roles in reducing inflammation in the airways and improving lung
function with relief of symptoms related to bronchospasm (Adams
2008; Walters 2007). Both are recommended when low dose ICS
alone is not sufficient to control asthma, which is at step three in
British asthma guidelines (BTS/SIGN 2008). Concerns have been
raised about the use of single inhaler LABA in chronic asthma, in
particular where it is used without a regular ICS, in relation to the
possible increased risk of severe adverse events and asthma-related
death (Cates 2008; Cates 2008a;Walters 2007). The concomitant
delivery of ICS and LABA avoids the inadvertent use of LABA
without prescribed ICS treatment.
Why it is important to do this review
It is recognised that many patients who are prescribed ICS do not
continue to take the treatment in clinical practice, and combina-
tion inhalers can increase ICS use both asmaintenanceDelea 2008
and single inhaler therapy Sovani 2008. Whilst the trials which
have investigated doubling the dose of ICS early in exacerbations
have been disappointing (FitzGerald 2004, Harrison 2004), there
is the potential with single inhaler therapy for the patient to au-
tomatically increase both LABA and ICS when their asthma is
worse and cut down again as their symptoms improve. This holds
out the prospect of maintaining control of asthma and preventing
exacerbations with lower overall exposure to ICS.
This review has identified and summarised clinical trials that com-
pare single inhaler therapy for maintenance and relief with budes-
onide/formoterol against maintenance with ICS and a separate
reliever therapy.
O B J E C T I V E S
To assess the efficacy and safety of budesonide/formoterol in a sin-
gle inhaler to be used for both maintenance and reliever therapy
in asthma in comparison to maintenance with inhaled corticos-
teroids (alone or as part of current best practice) and any reliever
therapy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised trials of parallel group design have been included in
the review.
Types of participants
Adults and children with a diagnosis of chronic asthma. We ac-
cepted trialist-defined asthma, recording the definition of asthma
used in the studies, and the entry criteria. We have summarised
baseline severity of lung function and persistence of symptoms,
and we collected data on pre-study maintenance therapies. We
did not include studies conducted in an emergency department
setting.
Types of interventions
Eligible treatment group intervention
This review included studies which have assessed the effects of
using a combined inhaled steroid and long-acting beta2-agonist
delivered through a single inhaler device for regular maintenance
and the relief of asthma symptoms.
Eligible control group treatment
The control groups for the studies in this review consisted of a pre-
scribed inhaled corticosteroid given as regular maintenance treat-
ment with a separate reliever inhaler.
Study duration was at least 12 weeks.
We did not consider studies that compared different combination
therapy inhalers (regular seretide versus regular symbicort has been
reviewed elsewhere Lasserson 2008), or titration of maintenance
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dosing of combination therapy based on clinical signs and symp-
toms.
Types of outcome measures
Primary outcomes
• Patients with exacerbations requiring hospitalisation
• Patients with exacerbations requiring oral corticosteroids
• Serious adverse events (including mortality and life-
threatening events)
• Growth (in children)
Secondary outcomes
• Severe Exacerbations (composite outcome of
hospitalisation/ER visit/oral steroid course)
• Diary card morning and evening peak expiratory flow (PEF)
• Clinic spirometry (FEV1)
• Number of rescue medication puffs required per day
• Symptoms/Symptom-free days
• Nocturnal awakenings
• Quality of life
Search methods for identification of studies
Electronic searches
Trials were identified using the Cochrane Airways Group Spe-
cialised Register of trials, which is derived from systematic searches
of bibliographic databases including the Cochrane Central Reg-
ister of Controlled Trials (CENTRAL), MEDLINE, EMBASE,
CINAHL, AMED, and PsycINFO, and handsearching of respira-
tory journals and meeting abstracts. All records in the Specialised
Register coded as ’asthma’ were searched using the following terms:
(“single inhaler therapy” or SiT or SMART or relie* or “as need*”
or as-need* or prn or flexible or titrat*) and ((combin* or symbicort
or viani) or ((steroid* or corticosteroid* or ICS or budesonide
or BUD or Pulmicort or beclomethasone or BDP or becotide)
and (“beta*agonist” or “beta*adrenergic agonist” or formoterol or
eformoterol or oxis or foradil)))
Date of last search was September 2008
Searching other resources
We contacted trialists and manufacturers in order to con-
firm data and to establish whether other unpublished or
ongoing studies are available for assessment. We hand-
searched clinical trials web sites (www.clinicalstudyresults.org;
www.clinicaltrials.gov; www.fda.gov) and the clinical trial web
sites of combination inhaler manufacturers (www.ctr.gsk.co.uk;
www.astrazenecaclinicaltrials.com).
Data collection and analysis
Selection of studies
Following electronic literature searches, two review authors (CC
& TL) independently selected articles on the basis of title and/or
abstract for full text scrutiny. The authors agreed a list of articles
which were retrieved, and subsequently assessed each study to de-
termine whether it was a secondary publication of a primary study
publication, and to determine whether the study met the entry
criteria of the review.
Data extraction and management
We extracted information from each study for the following char-
acteristics:
Design (description of randomisation, blinding, number of study
centres and location, number of study withdrawals).
Participants (N, mean age, age range of the study, gender ratio,
baseline lung function, % on maintenance ICS or ICS/LABA
combination & average daily dose of steroid (BDP equivalent),
entry criteria).
Intervention (type and dose of component ICS and LABA, control
limbdosing schedule, intervention limbdose adjustment schedule,
inhaler device, study duration & run-in)
Outcomes (type of outcome analysis, outcomes analysed)
Assessment of risk of bias in included studies
We assessed trial bias protection in the following domains study
quality according to whether studies meet the following pre-spec-
ified quality criteria (as met, unmet or unclear, Higgins 2008):
Sequence Generation
Allocation Concealment
Blinding of participants and investigators
Loss to follow-up
Measures of treatment effect
We extracted data for each of the outcomes considered by the
review from the trial publication(s) or from correspondence with
trialist or manufacturer. Exacerbations were the primary outcome
for this review and were reported by subtype (hospitalisation and
courses of oral steroids), rather than just as a composite outcome.
Serious adverse events were considered separately as fatal and non-
fatal events.
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Unit of analysis issues
We sought to obtain data from the trial sponsors that is reported
with patients (rather than events) as the unit of analysis for the
primary outcomes. Some patients may have suffered more than
one exacerbation over the course of the studies and these events
are not independent.
Data synthesis
Data were combined with RevMan 5.0, using a fixed effect mean
difference (calculated as a weighted mean difference) for continu-
ous data variables, and a fixed effect Odds Ratio for dichotomous
variables. When zero cells were present for an outcome in any of
the included studies the Peto Odds Ratio was used to combine the
results as it does not require a continuity correction to be used.
For the primary outcomes of exacerbations and serious adverse
events, when a significant Odds Ratio was found, we calculated
an NNT(benefit or harm) for the different levels of risk as repre-
sented by control group event rates over a specified time period
using the pooled Odds Ratio and its confidence interval (Visual
Rx).
Subgroup analysis and investigation of heterogeneity
We pooled the data from adults and children in subgroups. Adult
studies were considered as those which recruited participants from
18 years of age upwards. Adult and adolescent studies were con-
sidered as those which recruit participants from 12 years of age
upwards. We considered participants in studies where the upper
age limit was 12 years as children, and in studies where the upper
age limit was 18 years as children and adolescents. Subgroup anal-
ysis were not possible in relation to asthma severity and degree of
control of symptoms at baseline.
We measured statistical variation between combined studies by
the I2 statistic (Higgins 2003). Where this exceeded 20% we will
investigate the heterogeneity found, before deciding whether to
combine the study results for the outcome.
Sensitivity analysis
Sensitivity analysis were planned on the basis of risk of bias in
studies and methods of data analysis (fixed and random effects
models).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
The search was last carried out in September 2008 and included
198 citations. From these 51 were retrieved as full text articles,
representing 24 unique studies. There were 10 studies (21 cita-
tions) included in the review and 14 studies (31 citations) that
were excluded. Full details are given in the lists of Included stud-
ies and Excluded studies. Four further ongoing studies have been
identified from handsearching clinicaltrials.gov (NCT00463866;
NCT00628758; SYMPHONIE 2008; SPAIN 2008).
Included studies
All of the studies were on adults and adolescents with the exception
of STAY - Children, in which the results from the 224 children
included in the STAY study were reported in a separate paper by
Bisgaard. This has therefore been regarded separately from STAY
- Adults which reported the adult results from the STAY study.
The active treatment in most studies was budesonide/formoterol
160/4.5 mcg 1 Inhalation twice daily plus as-needed; this is the de-
livered dose and is the same as 200/6 mcg actuator dose described
in some of the studies. In STEAM the maintenance treatment
dose was the same but was given as two inhalations in the evening,
and in STAY - Children the maintenance dose was budesonide/
formoterol 160/4.5 mcg one inhalation in the evening.
Of the 10 adult studies, six studies compared single inhaler therapy
(SiT) to current best practice; these were DE-SOLO; MONO;
NCT00235911; SALTO; SOLO; STYLE. In these studies long-
acting beta2-agonists were allowed in the control arm, and many
of the participants were already using long-acting beta2-agonists.
The other four studies compare SiT to inhaled corticosteroids as
maintenance and terbutaline as reliever (Scicchitano 2004; STAY
- Adults; STEAM; Sovani 2008) and of these, the first three com-
pared SiT to a higher dose of maintenance ICS. In these studies
long-acting beta2-agonists were not allowed in the control arm,
and were withdrawn from those patients previously taking them.
Sovani 2008 compared to the same dose of ICS (as the main aim
of this study was to assess compliance with ICS).
Two large completed studies have not yet been reported in a paper
publication or on the sponsors web site of controlled trials. DE-
SOLO aimed to randomise 1600 participants and STYLE 1000
participants. Both compared SiT to current best practice so for
this comparison the results from2600 patient remain unpublished
out of 7000 patients who have completed trials, although for the
purpose of this review AstraZeneca have provided data on file for
the primary exacerbation outcomes from STYLE. There are also
three studies of similar size that are nearing completion and will
report on a further 3000 patients in comparison to current best
practice (NCT00628758; SPAIN 2008; SYMPHONIE 2008).
The reportedmean daily dose of inhaled corticosteroids previously
used by participants was high in most of the studies: MONO
(1035 mcg), SALTO (579 mcg), Scicchitano 2004 (746 mcg),
SOLO (569 mcg), Sovani 2008 (590 mcg, but poor compliance
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was an inclusion criterion), STAY - Adults (660 mcg), STAY -
Children (315 mcg). The mean daily dose was lower in STEAM
(340 mcg) and is not available from the other three studies (DE-
SOLO; NCT00235911; STYLE).
Inclusion criteria for DE-SOLO and SOLO were that the par-
ticipants had to be stable on a combination of LABA and ICS
or symptomatic on ICS maintenance, and MONO and SOLO
reported that 74% to75% of participants had previously taken
LABA as well as ICS before the trial. Scicchitano 2004, STAY -
Adults, and STAY - Children included participants who had suf-
fered a clinically important exacerbation in the previous year. In
SALTO 27% of patients were reported to have mild persistent
asthma, 37% moderate persistent and 36% severe persistent.
Some studies included a run-in of about twoweeks inwhich LABA
was withdrawn (Scicchitano 2004; STAY - All ages; STEAM) and
in the case of STEAM, the maintenance dose of ICS was reduced
from an average of 350 mcg/day to 200 mcg/day as well, and in
order to secure “a symptomatic population that could respond
differently to different treatments, patients were required to have
at least 7 inhalations of as-needed medication during the last 10
days of the run-in period”. SALTO and SOLO continued usual
therapy over the two week run-in period, but details of any run-
in period are not currently available for the other studies.
The primary outcomes for the studies are shown in the
Characteristics of included studies. For themajority of studies this
was time to first severe asthma exacerbation, which usually in-
cluded hospitalisation, visits to an emergency department, a course
of oral steroids and sometimes a 30% drop in peak expiratory flow
(PEF) such as in Scicchitano 2004; STEAM; STAY - Adults; STAY
- Children. The definition of severe exacerbation was not specified
in the current reports of DE-SOLO; MONO; NCT00235911;
SALTO or STYLE. Sovani 2008 had a different design from the
other studies and the primary outcome was the dose of inhaled
corticosteroids.
All of the studies (apart from Sovani 2008 and possibly
NCT00235911) are multi-centre studies, and no information has
been found in relation to differences between centres or countries
in any of these trials.
Excluded studies
The reasons for the exclusion of 14 studies is documented in the
Characteristics of excluded studies.
Risk of bias in included studies
The overview of risk of bias is shown in Figure 1
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
Few details are reported in relation to sequence generation and
allocation concealment.
Blinding
The studies comparing SiT with current best practice are un-
blinded, whilst those comparing with higher doses of inhaled cor-
ticosteroids are double-blind. Sovani 2008 was also unblinded as
adherence was the primary outcome for this study.
Incomplete outcome data
The trial reports are clear about the proportion of randomised
patients who were analysed inMONO; Scicchitano 2004; SOLO;
STAY - All ages; Sovani 2008, and the dropout rate does not raise
serious concerns.
Selective reporting
Missing trial reports
Noreported results have been found for two large studies including
around 2,600 participants (DE-SOLO; STYLE) out of around
7,000 patients comparing SiT to current best practice. Moreover
two other studies for this comparison have only been reported in
the form of a summary on the sponsors’ trial register (MONO;
SALTO).
Missing details of outcome data
Publication bias is a problem from the web reports which do not
present sufficient information to use for many outcomes. Hospi-
talisations tend to be reported as part of a combined outcome of
“severe” asthma exacerbation and are much rarer than courses of
oral corticosteroids. Separate outcome data for patients with at
least one asthma hospitalisation (or asthma SAE) and patients with
at least one course of oral corticosteroids have been requested from
the sponsor and have been obtained from MONO; Scicchitano
2004; STAY - Adults; STEAM; NCT00235911 and STYLE.
Other potential sources of bias
All of the included studies are sponsored or supported by As-
traZeneca, the manufacturers of Symbicort.
Effects of interventions
The primary outcomes for this review are exacerbations leading
to hospitalisation, exacerbations treated with a course of oral cor-
ticosteroids and serious adverse events. In general the trials have
reported composite outcomes that include the above types of exac-
erbation combined with Emergency Room (ER) visits and some-
times a 30% drop in peak flow. We have obtained data on our
primary outcomes from the trial sponsors. Most of the studies are
also multi-site randomised controlled trials and have not reported
data from any of the individual sites.
Adults and Adolescents treated with Single inhaler
Therapy compared to current best practice
Primary Outcomes
Exacerbations of asthma causing hospital admissions
There were 19 hospitalisations from a total of 5,378 participants
in the five trials providing data for this review (seven in the single
inhaler therapy arms and 12 in the current best practice arms of
MONO; NCT00235911; SALTO; SOLO and STYLE). SALTO
reports 2 asthma exacerbations that require hospitalisation in the
single inhaler therapy arm of the study, so this could represent 1
or 2 patients. In either case there is no significant difference in
the pooled outcome: (Peto OR 0.59; 95% CI 0.24 to 1.45) if this
is two patients, (Peto OR 0.51; 95% CI 0.20 to 1.29) if the two
events were in the same patient, see Figure 2.
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Figure 2. Forest plot of comparison: 1 Adults and Adolescents treated with Single Inhaler Therapy versus
Conventional Best Practice, outcome: 1.1 Patients with exacerbations causing hospitalisation.
Results from a further 4,600 patients in DE-SOLO;
NCT00628758; SPAIN 2008 and SYMPHONIE 2008 are
awaited.
Exacerbations of asthma treated with oral corticosteroids
We have obtained data from four studies (MONO,
NCT00235911, SOLO and STYLE, 4,470 participants) on pa-
tients with one or more courses of oral corticosteroids and the re-
duction with single inhaler therapy was not significant (OR 0.83;
95% CI 0.66 to 1.03). There were 153 of 2244 in the SiT arm
and 181 of 2226 in the current best practice arm who needed one
or more courses of oral steroids, see Figure 3. No data has been
made available from SALTO for this outcome, and again results
are awaited from the four trials described above.
Figure 3. Forest plot of comparison: 1 Adults and Adolescents treated with Single Inhaler Therapy versus
Conventional Best Practice, outcome: 1.2 Patients with exacerbations treated with oral steroids.
Serious adverse events
No significant difference was seen in either fatal or non-fatal seri-
ous adverse events from the combined results of MONO, SALTO
and SOLO; for fatal events (Peto OR 1.95; 95% CI 0.39 to 9.67)
Analysis 1.3, and for non-fatal events (OR 1.02; 95% CI 0.68
to 1.52) Analysis 1.4. However it should be pointed out that the
overall number of events (6 fatal and 102 non-fatal SAEs) was too
small to rule out the possibility of a clinically important increase
or decrease. Results from the currently unpublished studies above
may throw further light on these outcomes. Peto OR was used for
the fatal SAE analysis in view of the presence of two trials with no
deaths in the current best practice arms (MONO; SALTO).
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A post-hoc observation was that each of these three studies found a
higher number of discontinuations due to adverse events with sin-
gle inhaler therapy, and these were significantly raised in MONO
and SOLO, see Analysis 1.5. This finding requires further clarifi-
cation from the currently unpublished studies, and was attributed
by the investigators to patients in the SiT arm who changed from
MDI to dry-powder inhaler devices.
Secondary Outcomes
Severe exacerbations requiring medical intervention
There were 2143 patients on SiT compared with 2138 patients on
current best practice in MONO, SALTO and SOLO. There was
no overall significant reduction in the time to a serious exacerba-
tion, as defined by the investigators, (Hazard Ratio 0.96; 95% CI
0.85 to 1.07), Figure 4.
Figure 4. Forest plot of comparison: 1 Adults and Adolescents treated with Single Inhaler Therapy versus
Conventional Best Practice, outcome: 1.6 Patients with “severe” exacerbation (time to event).
Change in morning Peak Expiratory Flow
The change in morning PEF (% predicted) in SOLO was 1.00%
[95% CI -0.96 to 2.96] which was in favour of SiT, but neither
clinically nor statistically significant ( Analysis 1.7). Data were not
available for this outcome from MONO and SALTO.
Rescue Medication use
There was a difference of -0.16 [-0.27, -0.05] puffs per day of res-
cue medication use in the SiT arm of SOLO compared to current
best practice, Analysis 1.8.
Quality of Life (Change in ACQ score)
The two studies reporting this outcome had heterogeneous find-
ings (Analysis 1.9). SALTO demonstrated an improvement in the
ACQ score in favour of SiT, whilst in SOLO the direction of effect
favoured current best practice. The results have not been com-
bined in view of the heterogeneity (I2 = 84%) and quality of life
results are awaited from the other studies that have not yet been
reported.
Steroid load
All three published studies demonstrated a significantly lower in-
take of inhaled steroids in the SiT arms in comparison with cur-
rent best practice but again heterogeneity was high (I2 = 91%) and
the results were therefore not combined. It is expected that the size
of the reduction in ICS dose will reflect the trial design for each
study, giving rise to the heterogeneity, and in the mean differences
ranged from 107 mcg/day in SALTO to 267 mcg/day in SOLO
(Analysis 1.10).
Adults and Adolescents treated with Single inhaler
Therapy compared to maintenance Inhaled
Corticosteroids with separate reliever inhaler
Primary Outcomes
Exacerbations of asthma causing hospital admissions
Scicchitano 2004, STAY - Adults and STEAM contributed 4,209
participants to this outcome, and overall there were fewer admis-
sions on SiT in comparison to ICS, but this was not statistically
significant. The number of admitted patients was small (12 in to-
tal on SiT and 22 on ICS) and the pooled result is (Peto OR 0.56;
95% CI 0.28 to 1.09), as shown in Figure 5.
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Figure 5. Forest plot of comparison: 2 Adults and Adolescents treated with Single Inhaler Therapy versus
higher fixed dose ICS, outcome: 2.1 Patients with exacerbations causing hospitalisation.
The data used for Scicchitano 2004, STEAMwere on file fromAs-
traZeneca, and were reported as patients with at least one asthma-
aggravated serious adverse event that required hospitalisation. The
composite outcome of hospitalisation or ED visits was dominated
by participants attending ED and was therefore not used for this
outcome. In total 17 patients were admitted to hospital in com-
parison to 38 seen in ED from these two studies. Peto OR was
chosen for this meta-analysis as this method does not require a
continuity correction for zero cells. Sensitivity analysis usingMan-
tel-Haenszel OR gave very similar results (OR 0.56; 95% CI 0.28
to 1.11).
Exacerbations of asthma treated with oral corticosteroids
Scicchitano 2004, Sovani 2008, STAY - Adults and STEAM con-
tribute data on this outcome from4,280 participants; unpublished
data on file from AstraZeneca has been obtained from Scicchitano
2004 and STAY - Adults. The STAY - Adults paper reported de-
scriptive statistics only of courses of oral steroids per year, and in
adults this was 0.19 on SiT and 0.38 on budesonide. The pooled
result showed a significant reduction in the number of patients
requiring a course of steroids (OR 0.54; 95% CI 0.45 to 0.64)
and with a total of 228 patients with an event on SiT and 387
on budesonide, Figure 6. This translates into a number needed to
treat to prevent one patient needing oral corticosteroids over an
eleven month period of 14 (95% CI 12 to 18), see Figure 7.
Figure 6. Forest plot of comparison: 2 Adults and Adolescents treated with Single Inhaler Therapy versus
higher fixed dose ICS, outcome: 2.2 Patients with exacerbations treated with oral steroids.
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Figure 7. In the control group 18 people out of 100 had exacerbation treated with oral steroids over 11
months, compared to 11 (95% CI 9 to 12) out of 100 for the active treatment group. NNT(B) = 14, (95% CI 12
to 18).
Sensitivity analysis using random effects Mantel-Haenszel OR
gave a marginally wider confidence interval (OR 0.54; 95% CI
0.44 to 0.65). The design of Sovani 2008 was different from the
other studies in that adherence with inhaled corticosteroids was
the primary concern of the study.
Serious adverse events
No significant difference was seen in either fatal or non-fatal seri-
ous adverse events from the combined results of Scicchitano 2004,
STAY - Adults and STEAM; for fatal events (Peto OR 0.37; 95%
CI 0.05 to 2.62), and for non fatal events (OR 0.97; 95% CI
0.73 to 1.29). Again the number of events is small (4 fatal and
201 non-fatal) so the confidence interval includes the possibility
of important increase or decrease with SiT.
In contrast to the studies comparing SiT to current best practice,
a post hoc inspection of discontinuations due to adverse events
in Scicchitano 2004 and STEAM found a significant decrease in
favour of SiT.
Secondary Outcomes
Severe exacerbations requiring medical intervention
There were 1301 on SiT compared with 1285 on twice the dose
of budesonide in Scicchitano 2004 and STEAM. There was a sig-
nificant reduction in the time to a serious exacerbation, as defined
by the investigators, (Hazard Ratio 0.59; 95% CI 0.49 to 0.70),
Figure 8.
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Figure 8. Forest plot of comparison: 2 Adults and Adolescents treated with Single Inhaler Therapy versus
higher fixed dose ICS, outcome: 2.6 Patients with “severe” exacerbation (time to event).
Change in morning Peak Expiratory Flow and clinic FEV1
There was a significant increase in PEF in the SiT arms of
Scicchitano 2004, STAY -Adults and STEAM compared to higher
doses of budesonide (MD 22.29 L/min; 95% CI 17.62 to 26.95),
Analysis 2.7. Similarly an increase of FEV1 in favour of SiT was
found (MD 0.10 L ; 95% CI 0.07 to 0.13), Analysis 2.8.
Rescue Medication use
There was a reduction in rescue medication use in favour of SiT
(MD -0.37 puffs per day; 95% CI -0.49 to -0.25), Analysis 2.9.
Quality of Life (Change in ACQ score)
The only study reporting ACQ scores was Sovani 2008 and no
significant difference was found, Analysis 2.10.
Steroid load
Scicchitano 2004 reported a mean daily budesonide dose of 466
mcg/day in the SiT arm in comparison with 640 mcg/day in the
ICS arm, and1776days onoral corticosteroids in comparisonwith
3177 days. STAY - Adults does not report the mean daily doses of
budesonide, but does report 0.19 courses of oral corticosteroids per
year for SiT compared to 0.38 per year for higher dose budesonide.
STEAM reports a mean daily budesonide dose of 240 mcg/day
with SiT and 320 mcg/day in the higher dose ICS arm. However
the paper also reports five patients on SiT who had a mean daily
dose of > 640 mcg/day on SiT. Again STEAM reported a total of
114 days of oral corticosteroids with SiT and 498 days with higher
dose budesonide.
Sovani 2008 was designed to investigate whether single inhaler
therapy could overcome poor adherence with inhaled corticos-
teroids, and found an increase in mean daily use of budesonide
(448 versus 252 mcg/day, mean difference 196 mcg/day, 95% CI
113 to 279 mcg/day).
Children treated with Single inhaler Therapy
compared to higher doses of Inhaled Corticosteroids
Primary Outcomes
Exacerbations of asthma causing hospital admissions
It has been possible to obtain clarification from the sponsors in re-
lation to the hospitalisations for children in each treatment arm of
STAY - Children. Hospitalisations related to asthma are reported
as none on SiT and one with ICS (this does not quite match the
asthma SAE data, as one child was already in hospital with laryn-
gitis, and the stay was prolonged due to an asthma exacerbation)
Analysis 3.1. These events are too few to draw any conclusions.
Exacerbations of asthma treated with oral corticosteroids
The only information in the report of STAY - Children in relation
to oral corticosteroid use relates to the total number of treatment
days in each group (32 days for SiT and 141 days for ICS). This
is not suitable for use in meta-analysis as there is no report of
how many children were treated with oral corticosteroids in each
group. The sponsors have not been able to provide this data.
Serious Adverse Events
There were no fatal serious adverse events in STAY - Children
and non-fatal events occurred in 2 out of 118 children on SiT
compared to 5 out of 106 on ICS (a non-significant reduction)
Analysis 3.3.
Annual Height gain
The mean increase in height over one year in the SiT group was
5.3 cm (range 1 to 14 cms) and in the ICS group themean increase
was 4.3 cm (range -2 to 15 cm). The fact that some children appear
to have become shorter raises concerns about the accuracy of the
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measurements carried out in some of the 246 centres (as the paper
reports that local procedures were used to measure height), but
the average advantage of 1 cm for SiT was statistically significant
(95% CI 0.3 to 1.7 cms) Analysis 3.4.
Secondary Outcomes
Severe exacerbations requiring medical intervention
There were nine patients on SiT with exacerbations requiring
medical intervention (hospitalisation or ER visit or course of oral
steroids) which was significantly less than the 21 patients given
ICS, (OR from this single study 0.33 [0.15, 0.77]).
Change in morning Peak Expiratory Flow
The children given SiT therapy in STAY - Children had an average
increase inmorning PEF of 12Litres/min [95%CI: 4.55 to 19.45]
in comparison with those given ICS.
Clinic Spirometry (FEV1)
There was no significant difference in FEV1 between the SiT and
ICS groups in STAY - Children (0.10 Litres [95% CI: -0.14,
0.34]).
Nocturnal Awakenings
There were, on average, two less nocturnal awakenings per night
for children on SiT than those on ICS in STAY - Children (-2.00
[-3.33, -0.67]).
Steroid load
The mean daily dose of budesonide in children given SiT in STAY
- Children was 126 mcg/day in comparison to 320 mcg/day in
the group randomised to fixed dose budesonide. There were also
less days spent on oral corticosteroids in the SiT group (32 v 141
days). Two of 51 children given SiT had abnormally low cortisol
levels in comparison with three of 41 on ICS, a non significant
reduction (OR = 0.52 [0.08, 3.25]).
D I S C U S S I O N
Summary of main results
In comparison to common best practice, which allowed the use of
long-acting beta2-agonists in the control arms, four large studies
(MONO; SALTO, SOLO and STYLE) on 5,378 patients have
not demonstrated significant advantages for SiT in exacerbations
needing medical intervention. There was no significant difference
found in fatal or non-fatal serious adverse events. All three pub-
lished studies found a reduction in ICS dose when using SiT. The
full results from further studies, which aimed to recruit a further
5600 patients, are awaited (DE-SOLO; STYLE; SPAIN 2008;
SYMPHONIE 2008; NCT00628758).
In contrast, in comparison to higher maintenance doses of budes-
onide (with no long-acting beta2-agonists in the control arms),
four studies (Scicchitano 2004, STAY - Adults, STEAM and
Sovani 2008) on 4,280 patients demonstrated significant reduc-
tions in patients with an exacerbation needing oral steroids (OR
0.54; 95% CI 0.45 to 0.64) but not on exacerbations leading to
hospitalisation (Peto OR 0.56; 95% CI 0.28 to 1.09). There was
no significant difference found in fatal or non-fatal serious adverse
events. The studies found a reduction in ICS dose when using SiT.
Sovani 2008 demonstrated increased adherence with inhaled cor-
ticosteroids using single inhaler therapy in comparison to mainte-
nance budesonide at the same dose.
Only one study included 224 children (STAY - Children) and
compared SiT to four times the dose of regular budesonide. There
was a significant reduction in exacerbations needing increase in in-
haled steroid treatment and/or additional treatment in this study,
but only two hospitalised patients and no separate data on courses
of oral corticosteroids. There was no significant difference found
in fatal or non-fatal serious adverse events. Less inhaled and oral
corticosteroids were used in the SiT group and the annual height
gain was also greater in the SiT group.
Overall completeness and applicability of
evidence
All the included studies have been sponsored by AstraZeneca, and
large numbers of patients that have been studied or are in ongoing
trials are still unreported. For this reason we would regard the cur-
rent evidence as provisional until further data becomes available.
This is especially relevant to trials comparing SiT with current
best practice, and the results in children, in whom the use of long-
acting beta2-agonists is more contentious (Bisgaard 2003).
It is possible that the difference between the results in trials com-
paring SiT with current best practice as opposed to higher doses
of ICS alone as a comparison arm could relate to the design of
the trials. Many of the patients in the control arm of the current
best practice trials were probably taking long-acting beta2-ago-
nists (as previous long-acting beta2-agonists was around 75% in
MONO and SOLO), whereas none of the control arm patients in
the higher dose maintenance ICS were taking long-acting beta2-
agonists (as they were withdrawn from those patients previously
using them).
The inclusion of patients who were symptomatic during run-in
periods in which LABA was withdrawn may favour SiT, as for-
moterol would be expected to control symptoms more quickly
than inhaled corticosteroids in Scicchitano 2004, STEAM and
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STAY - All ages. There is some suggestion that this may have oc-
curred from the plots of individual patient exacerbations that show
steeper gradients initially for the budesonide arms of these trials
but similar gradients in the two groups towards the end of the
study period.
This implies that the current evidence comparing SiT tofixeddoses
of ICS can be applied directly only to patients who become symp-
tomatic when maintenance treatment with ICS (with or without
LABA) is reduced. How these results should be extrapolated to
other groups of patients remains a matter for debate.
Quality of the evidence
Despite sparse information on sequence generation and allocation
concealment, we concluded that as all the studies were regula-
tory studies, the risk of bias in these domains is low. The studies
comparing SiT with current best practice were not blinded, whilst
those that compared SiT to fixed doses of ICS were blinded. Al-
though bias could have been introduced in the former, the treat-
ment effects in comparison with current best practice are generally
smaller.
Agreements and disagreements with other
studies or reviews
We agree with the reservations voiced by Lipworth 2008 in his re-
sponse in theBMJ to the reviewbyBarnes 2007.The run-in for the
trials comparing SiT with fixed dose inhaled corticosteroids was
designed to select patients who became symptomatic when their
maintenance treatment was reduced or when long-acting beta2-
agonists were withdrawn. This feature of the trial design may con-
tribute to the improvement in time to first asthma exacerbation
on SiT, because the onset of action of higher dose inhaled corti-
costeroids would be expected to be slower, and more patients may
therefore have suffered an early exacerbation in the higher dose
inhaled corticosteroid arm of the trials.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Single inhaler therapy can reduce the risk of asthma exacerbations
needing oral corticosteroids in comparisonwith fixed dosemainte-
nance inhaled corticosteroids. Guidelines and common best prac-
tice suggest the addition of regular long-acting beta2-agonist to
inhaled corticosteroids for uncontrolled asthma, and single inhaler
therapy has not been demonstrated to significantly reduce exacer-
bations in comparison with current best practice, although results
of five large trials are awaiting publication. Single inhaler therapy
is not currently licensed for children under 18 years of age in the
United Kingdom.
Implications for research
The majority of trials comparing single inhaler therapy to current
best practice have not been fully published, and we have chosen
not to suggest implications for further research on adults until
these results are known. There is very little current evidence with
respect to children.
A C K N OW L E D G E M E N T S
We thank Susan Hansen and Elizabeth Arnold of the Cochrane
Airways Group for their assistance in searching for trials and ob-
taining the abstracts and full reports, and JohnWhite for editorial
help. We also thank Robyn Von Maltzahn and Joe Gray from As-
traZeneca for help in obtaining data from MONO, Scicchitano
2004, STEAM, STAY - All ages and STYLE. Thanks also to He-
len Reddel for pointing out the typological errors that have been
corrected in this amendment.
R E F E R E N C E S
References to studies included in this review
DE-SOLO {unpublished data only}
∗ AstraZeneca (D5890L00011). DESOLO - SiT Peri-
Launch: a comparison of symbicort single inhaler therapy
and conventional best practice for the treatment of
persistent asthma in adults. clinicaltrials.gov 2005:http://
www.clinicaltrials.gov/ct/show/NCT00252863 [Accessed
3rd September 2008].
MONO {published data only}
AstraZeneca (D5890L00008). MONO: Symbicort single
inhaler therapy and conventional best standard treatment
for the treatment of persistent asthma in adolescents and
adults. clinicaltrials.gov 2006:http://www.clinicaltrials.gov/
ct/show/NCT00242411 [Accessed 12/04/2006].
NCT00235911 {unpublished data only}
AstraZeneca (BN-00S-0011). Symbicort single inhaler
therapy for asthma in a general practice setting.
www.clinicaltrials.gov 2005:http://www.clinicaltrials.gov/
ct/show/NCT00235911 [Accessed 22/02/2008].
SALTO {published data only}
AstraZeneca (D5890L00009). SALTO - symbicort single
inhaler therapy use in adolescent adults and adults with
persistent asthma. www.clinicaltrials.gov 2006:http://
15Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in
adults and children (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
www.clinicaltrials.gov/ct/show/NCT00290264 [Accessed
22/02/2008].
Scicchitano 2004 {published data only}
Scicchitano R, Aalbers R, Ukena D, Manjra A, Fouquert
L, Centann S, et al.Efficacy and safety of budesonide/
formoterol single inhaler therapy versus a higher dose of
budesonide in moderate to severe asthma. Current Medical
Research & Opinion 2004;20(9):1403–18.
SOLO {published data only}
Sears MR, Boulet L-P, Laviolette M, FitzGerald J Mark,
Bai TR, et al.Budesonide/formoterol maintenance and
reliever therapy: impact on airway inflammation in asthma.
European Respiratory Journal 2008:Epub: doi: 10.1183/
09031936.00104007.
Sears R, Boulet L-P, Laviolette M, FitzGerald JM, Bai
R, SmiljanicGeorijev N, et al.Budesonide/formoterol
maintenance and reliever therapy for asthma compared to
conventional best practice a randomised real life study.
European Respiratory Journal 2006;28(Suppl 50):613s.
Sovani 2008 {published data only}
Sovani MP, Whale CI, Oborne J, Cooper S, Mortimer K,
Ekström T, et al.Poor adherence with inhaled corticosteroids
for asthma: can using a single inhaler containing budesonide
and formoterol help?. British Journal of General Practice
2008;58(546):37–43.
STAY - Adults {published and unpublished data}
Bateman ED, Palmqvist M, Juniper EF, Zhu Y, Ekstrom
T. Single inhaler therapy with budesonide/formoterol has
superior efficacy to fixed-dose budesonide/formoterol or
a higher dose of budesonide alone. American Thoracic
Society 100th International Conference, May 21-26, 2004,
Orlando. 2004.
Bruce SA, Scherer YK. Maintenance and symptom relief
with budesonide plus formoterol reduced severe asthma
exacerbations. Evidence-Based Nursing 2005;8(3):78.
Jönsson BG, Berggren FE, Svensson K, O’Byrne PM.
Budesonide and formoterol in mild persistent asthma
compared with doubling the dose of budesonide - a cost-
effectiveness analysis. European Respiratory Journal. 2001;
Vol. 18, issue Suppl 33:517s.
Jönsson BG, Berggren FE, Svensson K, O’Byrne PM.
Economic results of adding formoterol to budesonide in
mild persistent asthma. European Respiratory Journal
2001; Vol. 18, issue Suppl 33:331s.
O’Byrne PM. Acute asthma intervention: Insights from the
STAY study. Journal of Allergy & Clinical Immunology 2007;
119(6):1332–6.
O’Byrne PM, Bisgaard H, Godard PP, Pistolesi M,
Palmqvist M, Zhu Y, Ekstrom T, Bateman ED. Budesonide/
formoterol combination therapy as both maintenance
and reliever medication in asthma. American Journal of
Respiratory & Critical Care Medicine 2005;171(2):129–36.
O’Byrne PM, Godard P, Pistolesi M, Ekstrom T. Single
inhaler therapy with budesonide/formoterol improves
asthma control compared with fixed dosing with
budesonide/formoterol or a higher dose of budesonide alone
[Abstract]. American Thoracic Society 100th International
Conference, May 21-26, 2004, Orlando. 2004:Poster J93.
SD-039-673. Efficacy and safety of budesonide/formoterol
(Symbicort) Turbuhaler® as Single Therapy in patients
with mild-moderate asthma. Comparison with Symbicort
Turbuhaler and Pulmicort® Turbuhaler as maintenance
therapy, both complemented with Bricanyl® Turbuhaler
(STAY). http://www.astrazenecaclinicaltrials.com 2006.
STAY - All ages {published and unpublished data}
O’Byrne PM, Bisgaard H, Godard PP, Pistolesi M,
Palmqvist M, Zhu Y, Ekstrom T, Bateman ED. Budesonide/
formoterol combination therapy as both maintenance
and reliever medication in asthma. American Journal of
Respiratory & Critical Care Medicine 2005;171(2):129–36.
STAY - Children {published and unpublished data}
Bisgaard H, Hultquist C. Budesonide/formoterol for
maintenance and as needed - a new approach to asthma
management in children [Abstract]. European Respiratory
Journal 2005;26(Suppl 49):Abstract No. 1060.
∗ Bisgaard H, Le Roux P, Bjamer D, Dymek A, Vermeulen
JH, Hultquist C. Budesonide/formoterol maintenance plus
reliever therapy - a new strategy in pediatric asthma. Chest
2006;130(6):1733–43.
O’Byrne PM. Acute asthma intervention: Insights from the
STAY study. Journal of Allergy & Clinical Immunology 2007;
119(6):1332–6.
O’Byrne PM, Bisgaard H, Godard PP, Pistolesi M,
Palmqvist M, Zhu Y, Ekstrom T, Bateman ED. Budesonide/
formoterol combination therapy as both maintenance
and reliever medication in asthma. American Journal of
Respiratory & Critical Care Medicine 2005;171(2):129–36.
SD-039-673. Efficacy and safety of budesonide/formoterol
(Symbicort) Turbuhaler® as Single Therapy in patients
with mild-moderate asthma. Comparison with Symbicort
Turbuhaler and Pulmicort® Turbuhaler as maintenance
therapy, both complemented with Bricanyl® Turbuhaler
(STAY). http://www.astrazenecaclinicaltrials.com 2006.
STEAM {published data only}
Astrazenca (SD-039-0667). Efficacy and Safety of
Symbicort® Turbuhaler® as Single Therapy in Patients
with Mild to Moderate Asthma - STEAM (SD-039-
0667). Astrazeneca Clinical Trials Register 2005:http://
www.astrazenecaclinicaltrials.com (accessed 20th February
2008).
Rabe KF, Pizzichini E, Stallberg B, Romero S, Balanzat AM,
Atienza T, et al.Budisonide/formoterol in a single inhaler
for maintenance and relief in mild-to-moderate asthma: A
randomized, double-blind trial. Chest 2006;129:245–56.
STYLE {published data only}
∗ AstraZeneca (D5890L00014). STYLE - symbicort single
inhaler therapy vs. conventional therapy in treatment of
persistent asthma. www.clinicaltrials.gov 2005:http://
www.clinicaltrials.gov/ct/show/NCT00252824 [Accessed
22/02/2008].
References to studies excluded from this review
16Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in
adults and children (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Balanzat 2004 {published data only}
Balanzat A, Centanni S, Palmqvist M, Rabe K. Budesonide/
formoterol single inhaler therapy reduces over reliance
on rapid acting reliever medication [Abstract]. European
Respiratory Journal 2004;24(Suppl 48):344s.
Bousquet 2007 {unpublished data only}
Astrazeneca (D5890C00002). Efficacy and safety of
Symbicort®Turbuhaler®160/4.5 mcg/inhalation, two
inhalations twice daily plus as-needed compared with
Seretide™ Diskus™ 50/500 mcg/inhalation, one
inhalation twice daily plus terbutaline Turbuhaler 0.4 mg/
inhalation as-needed - a 6-month, randomised, double-
blind, parallel-group, active controlled, multinational phase
IIIB study in adult and adolescent patients with persistent
asthma. AstraZeneca Clinical Trials Register 2006, issue
www.astrazenecaclinicaltrials.com (accessed 21/02/2008).
Bousquet J, Boulet L-P, Peters MJ, Magnussen H, Quiralte
J, Martinez-Aguilar NE, et al.Budesonide/formoterol for
maintenance and relief in uncontrolled asthma vs. high-
dose salmeterol/fluticasone. Respiratory Medicine 2007;101
(12):2437–46.
COMPASS {published and unpublished data}
AstraZeneca. SYM/050/DEC2007. Data on File.
Bleecker ER, Postma DS, Lawrance R, Meyers DA,
Ambrose H, Goldman M. Effect of polymorphisms in the
beta2-adrenergic receptor gene (ADRB2) on response to
long-acting beta2-agonist (LABA) therapy. Journal Allergy
and Clinical Immunology 2007;119(2):523.
Buhl R, Vogelmeier C. Budesonide/formoterol maintenance
and reliever therapy: a new treatment approach for adult
patients with asthma. Current Medical Research and Opinion
2007;23(8):1867–78.
Kuna P, Peters MJ, Buhl R. Budesonide/formoterol
as maintenance and reliever therapy reduces asthma
exacerbations a higher maintenance dose of budesonide/
versus formoterol or salmeterol/fluticasone. European
Respiratory Journal 2006;28(Suppl 50):205s.
Kuna P, Peters MJ, Manjra AI, Jorup C, Naya IP, Martinez-
Jimenez NE, et al.Effect of budesonide/formoterol
maintenance and reliever therapy on asthma exacerbations.
International Journal of Clinical Practice 2007;61(5):
725–36.
Price D, Wiren A, Kuna P. Budesonide/formoterol (B/F) as
maintenance and relief for asthma improves efficacy and
is cost saving versus higher maintenance dose of B/F or
salmeterol/fluticasone (S/F) [Abstract]. European Respiratory
Journal 2006;28(Suupl 50):214s.
Price D, Wiren A, Kuna P. Cost-effectiveness of budesonide/
formoterol for maintenance and reliever asthma therapy.
Allergy 2007;62(10):1189–98.
COSMOS {published data only}
Buhl R, Vogelmeier C. Budesonide/formoterol maintenance
and reliever therapy: a new treatment approach for adult
patients with asthma. Current Medical Research and Opinion
2007;23(8):1867–78.
D’Urzo A, Vogeimeier C, Jaspal M, Merino JM, Boulet S.
Symbicort (budesonide/formoterol) for both maintenance
and relief reduces the exacerbation burden compared
with titration of seretide (salmeterol/fluticasone) in
patients with asthma, a real life stud. American Thoracic
Society International Conference; May 20-25; San Diego,
California. 2005:Poster G24.
Johansson G, Andreasson EB, Larsson PE, Vogelmeier
CF. Cost effectiveness of budesonide/formoterol for
maintenance and reliever therapy versus salmeterol/
fluticasone plus salbutamol in the treatment of asthma.
Pharmacoeconomics 2006;24(7):695–708.
Vogelmeier C, D’Urzo A. Maintenance plus as-needed
budesonide/formoterol vs salmeterol/fluticasone in a real-
life setting. European Respiratory Journal 2005;26(Suppl
49):Abstract No. 2770.
Vogelmeier C, D’Urzo A, Jaspal M, Merino JM, Johansson
G, Boulet S. Symbicort for both maintenance and relief
reduces exacerbations compared with a titration of Seretide
(Advair) in patients with asthma: a real life study. American
Thoracic Society 2005 International Conference; May 20-
25; San Diego, California. 2005:Poster F67.
Vogelmeier C, D’Urzo A, Pauwels R, Merino JM, Jaspal M,
Boutet S, et al.Budesonide/formoterol maintenance and
reliever therapy: An effective asthma treatment option?.
European Respiratory Journal 2005;26(5):819–28.
D5890C00003 {published data only}
AstraZeneca (D5890C00003). A comparison of the control
of asthma inflammation provided by Symbicort turbuhaler
160/4.5 mcg/inhalation bid plus as-needed versus symbicort
turbuhaler 320/9 mcg/inhalation bid plus Pulmicort
turbuhaler 400mcg/dose bid plus terbutaline turbuhaler
0.4mg/inhalation as-needed. www.clinicaltrials.gov 2006:
http://www.clinicaltrials.gov/ct/show/NCT00244608
[Accessed22/02/2008].
Ind 2002 {published data only}
Ind PW, Villasante C, Shiner RJ, Pietinalho A, Boszormenyi
NG, Soliman S, Selroos O. Safety of formoterol by
Turbuhaler as reliever medication compared with terbutaline
in moderate asthma. European Respiratory Journal 2002;20
(4):859–66.
Jenkins 2007 {published data only}
Jenkins CR, Marks GB, Gibson PG, Wark PAB, Thien FC,
Belousova EG, et al.A randomised controlled trial of two
algorithms for maintaining asthma control on long-acting
bronchodilators (LABA) and inhaled corticosteroids (ICS).
Thoracic Society of Australia and New Zealand Annual
Scientific Meeting, 25-28 March 2007, Auckland. 2007:
Abstract TP044.
Jonkers 2006 {published data only}
Jonkers RE, Bantje TA, Aalbers R. Onset of relief of
dyspnoea with budesonide/formoterol or salbutamol
following methacholine-induced severe bronchoconstriction
in adults with asthma: a double-blind, placebo-controlled
study. Respiratory Research 2006;7:141.
Loukides 2005 {published data only}
Loukides S, Papageorgiou M, Karokis A, Zervas E,
Christodoulopoulou A, Papageorgiou N, et al.Single inhaler
therapy (SiT) with budesonide/formoterol (BUD/FUM) is
17Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in
adults and children (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
effective in asthma control. European Respiratory Journal.
2005; Vol. 26(Suppl 49):124S.
Lundborg 2006 {published data only}
Astrazeneca (LD-039-0003). An open, randomized,
parallel-group, multicentre, phase IIIB study to evaluate
the efficacy of Symbicort® Turbuhaler® single inhaler
therapy (SiT), given as a low maintenance dose once
or twice daily plus as needed, compared to a higher
maintenance dose of Symbicort Turbuhaler given
twice daily plus Oxis® Turbuhaler® as needed during
24 weeks in asthmatic patients (LD-039-0003).
AstraZeneca Clinical Trials Register 2006, issue http://
www.astrazenecaclinicaltrials.com/ncmprint.aspx?type=
article&param=516829 (accessed 21st February 2008).
Lundborg M, Wille S, Bjermer L, Tilling B, Lundgren
M, Telg G, et al.Maintenance plus reliever budesonide/
formoterol compared with a higher maintenance dose
of budesonide/formoterol plus formoterol as reliever in
asthma: An efficacy and cost-effectiveness study. Current
Medical Research & Opinion 2006;22(5):809–21.
Richter 2007 {published data only}
Richter K, Hartmann U, Metzenauer P, Magnussen H.
Randomised trial comparing as-needed versus regular
treatment with formoterol in patients with persistent
asthma. Respiratory Medicine 2007;101(3):467–75.
SMILE {published and unpublished data}
Rabe F, Atienza T, Magyar P, Larsoon P, Jorup C, Lalloo
G. A new combination therapeutic approach challenging
the current dogma of using inhaled corticosteroids as
maintenance only to control asthma. European Respiratory
Journal 2006;28(Suppl 50):666s.
Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo
UG. Effect of budesonide in combination with formoterol
for reliever therapy in asthma exacerbations: a randomised
controlled, double-blind study. Lancet 2006;938(9537):
744–53.
SOMA {published and unpublished data}
Haahtela T, Tamminen K, Malmberg LP, Zetterstrom O,
Karjalainen J, Yla-Outinen H, et al.Formoterol as needed
with or without budesonide in patients with intermittent
asthma and raised NO levels in exhaled air: A SOMA study.
European Respiratory Journal 2006;28(4):748–55.
Haahtela T, Tamminen K, Malmberg P, Karjalainen J, Yia-
Outinen H, Zetterstrom O, et al.As-needed treatment
with a b2-agonist/ corticosteroid combination in mild
intermittent asthma (SOMA). European Respiratory Journal
2005;26(Suppl 45):Abstract No. 1722.
Tattersfield 2001 {published data only}
Berggren F, Ekström T. A cost-effectiveness study comparing
the as-needed use of formoterol (Oxis) and terbutaline
(Bricanyl) in patients with moderate to severe asthma.
Respiratory Medicine 2001;98(9):753–8.
Tattersfield AE, Löfdahl CG, Postma DS, Eivindson A,
Schreurs AGM, Rasidakis A, et al.Comparison of formoterol
and terbutaline for as-needed treatment of asthma: a
randomised trial. Lancet 2001;357(9252):257–61.
References to ongoing studies
NCT00463866 {unpublished data only}
NCT00463866. Ongoing study March 2007.
NCT00628758 {unpublished data only}
NCT00628758. Ongoing study March 2006.
SPAIN 2008 {unpublished data only}
Study SPAINA Comparison of Symbicort Single Inhaler
Therapy (Symbicort Turbuhaler 160/4.5 mcg, 1 Inhalation
b.i.d. Plus as Needed) and Conventional Best Practice for
the Treatment of Persistent Asthma in Adults - a 26-Week,
Randomised, Open-Label, Parallel-Group, Multicentre
Study. Estimated enrolment: 1000. Ongoing study Sept
2006.
SYMPHONIE 2008 {unpublished data only}
SYMPHONIE. Ongoing study Sept 2005.
Additional references
Adams 2008
Adams NP, Bestall JC, Lasserson TJ, Jones PW, Cates CJ.
Fluticasone versus placebo for chronic asthma in adults and
children. Cochrane Database of Systematic Reviews 2008,
Issue 4. [DOI: 10.1002/14651858.CD003135.pub4]
Barnes 2007
Barnes PJ. Using a combination inhaler (budesonide plus
formoterol) as rescue therapy improves asthma control. Bmj
2007; Vol. 335, issue 7618:513–.
Bisgaard 2003
Bisgaard H. Effect of long-acting Beta2 agonists on
exacerbation rates of asthma in children. Pediatric
Pulmonology 2003; Vol. 36, issue 5:391–8. [: 1099–0496]
BTS/SIGN 2008
British Thoracic Society. British Guidelines on Asthma
Management. Thorax 2008; Vol. 63, issue Suppl 1.
Cates 2008
Cates CJ, Cates MJ. Regular treatment with salmeterol for
chronic asthma: serious adverse events (Cochrane Review).
Cochrane Database of Systematic Reviews 2008, Issue 3.
[DOI: 10.1002/14651858.CD006363.pub2]
Cates 2008a
Cates Christopher J, Cates Matthew J, Lasserson
Toby J. Regular treatment with formoterol for chronic
asthma: serious adverse events. Cochrane Database
of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/
14651858.CD006923.pub2]
Delea 2008
Delea TE, Hagiwara M, Stanford RH, Stempel DA. Effects
of fluticasone propionate/salmeterol combination on
asthma-related health care resource utilization and costs
and adherence in children and adults with asthma. Clinical
Therapeutics 2008; Vol. 30, issue 3:560–71.
FitzGerald 2004
FitzGerald JM, Becker A, Sears MR, Mink S, Chung K, Lee
J. Doubling the dose of budesonide versus maintenance
18Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in
adults and children (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
treatment in asthma exacerbations. Thorax 2004; Vol. 59,
issue 7:550–6.
Greenstone 2005
Greenstone IR, Ni Chroinin MN, Masse V, Danish A,
Magdalinos H, Zhang X, et al.Combination of inhaled
long-acting beta2-agonists and inhaled steroids versus
higher dose of inhaled steroids in children and adults with
persistent asthma. Cochrane Database of Systematic Reviews
2005, Issue 4. [DOI: 10.1002/14651858.CD005533]
Harrison 2004
Harrison T, Oborne J, Newton S, Tattersfield A. Doubling
the dose of inhaled corticosteroid to prevent asthma
exacerbations: randomised controlled trial. Lancet 2004;
Vol. 363, issue 9405:271–5.
Higgins 2003
Higgins JPT, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency in meta-analyses. BMJ 2003;327:
557–60.
Higgins 2008
Higgins JPT, Green S (editors). Cochrane Handbook for
Systematic Reviews of Interventions Version 5.0.0 [updated
February 2008] Available from: www.cochrane-handbook.org.
The Cochrane Collaboration, 2008.
Lasserson 2008
Lasserson TJ, Cates CJ, Ferrara G, Casali L. Combination
fluticasone and salmeterol versus fixed dose combination
budesonide and formoterol for chronic asthma in adults and
children. Cochrane Database of Systematic Reviews 2008,
Issue 3. [DOI: 10.1002/14651858.CD004106.pub3]
Lipworth 2008
Lipworth BJ, Jackson C. A SMART choice for primary care
asthma therapy?. http://www.bmj.com/cgi/eletters/335/
7618/513#178078 13 October 2007.
Ni Chroinin 2005
Ni Chroinin M, Greenstone IR, Danish A, Magdolinos H,
Masse V, Zhang X, et al.Long-acting beta2-agonists versus
placebo in addition to inhaled corticosteroids in children
and adults with chronic asthma. Cochrane Database of
Systematic Reviews 2005, Issue 4. [Art. No.: CD005535.
DOI: 10.1002/14651858.CD005535]
Palmqvist 2001
Palmqvist M, Arvidsson P, Beckman O, Peterson S, Lotvall
J. Onset of bronchodilation of budesonide/formoterol
vs. salmeterol/fluticasone in single inhalers. Pulmonary
Pharmacology & Therapeutics 2001;14(1):29–34.
Tattersfield 1999
Tattersfield AE, Postma DS, Barnes PJ, Svensson K,
Bauer CA, O’Byrne PM, et al.Exacerbations of asthma: a
descriptive study of 425 severe exacerbations. The FACET
International Study Group. American Journal of Respiratory
& Critical Care Medicine 1999;160(2):594–9.
Walters 2007
Walters EH, Gibson PG, Lasserson TJ, Walters JAE. Long-
acting beta2-agonists for chronic asthma in adults and
children where background therapy contains varied or no
inhaled corticosteroid. Cochrane Database of Systematic
Reviews 2007, Issue 1. [Art. No.: CD001385. DOI:
10.1002/14651858.CD001385.pub2]
∗ Indicates the major publication for the study
19Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in
adults and children (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
DE-SOLO
Methods A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbuhaler 160/4.5 µg,
1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment
of Persistent Asthma in Adults - a 26-Week, Randomised, Open-Label, Parallel-Group,
Multicentre Study. Dec 2004 to October 2006. 169 centres in Germany. No report of
run-in
The purpose of this study is to determine whether Symbicort dosed according to the
SymbicortMaintenance and Reliever Therapy (SMART) concept is superior to standard
asthma treatment according to the local German treatment guidelines
Participants Estimated enrolment: 1600. Patients 18 years or older
Inclusion Criteria:
• Patients with asthma, either well-controlled on a regular therapy with a
combination of long-acting beta-agonists and inhaled corticosteroids or symptomatic
on therapy with inhaled corticosteroids alone.
Exclusion Criteria:
• Any other significant lung disease other than asthma
• Any disease that might put patients at risk if they participate in the study
Interventions 1. Symbicort Turbuhaler 160/4.5 µg, 1 Inhalation b.i.d. Plus as Needed
2. Conventional Best Practice
Outcomes Primary Outcome Measures:
• Time to first severe asthma exacerbation
Secondary Outcome Measures:
• Number of severe asthma exacerbations
• Mean use of as-needed medication
• Change in forced expiratory volume in 1 second (FEV1) from the end of run-in
to the end of the study period
• Prescribed asthma medication during the treatment period
• Asthma Control Questionnaire (ACQ)
• Patient’s satisfaction with the treatment question
• Health care contacts
• Asthma medication
• Time lost from paid and unpaid work
• Serious adverse events (SAEs)
• Discontinuations due to adverse events (AEs)
Definition of severe exacerbation
Not specified
Notes No published results found for this study in September 2008
Risk of bias
Item Authors’ judgement Description
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DE-SOLO (Continued)
Adequate sequence generation? Unclear No details
Allocation concealment? Unclear No details
Blinding?
All outcomes
No Open
Incomplete outcome data addressed?
All outcomes
Unclear No details
MONO
Methods This was a randomised, open-label, parallel-group, Multicentre study in 1900 patients
(planned number) with persistent asthma. Patients were treated with either Symbicort®
SMART (i.e. Symbicort® Turbuhaler® (budesonide/formoterol) 160/4.5 µg (delivered
dose), 1 inhalation b.i.d. plus as needed), or conventional best practice according to the
investigator’s judgement, following GINA guidelines (Ref: Global Initiative for Asthma
2002). The treatment period lasted for 26 weeks, with no mention of any run-in period
This study was conducted in Denmark (123 centres), Finland (69 centres) and Norway
(83 centres) between September 2004 and October 2006
Participants 1854 patients were randomised, 1835 took at least one treatment and contributed to
the analysis, and 1667 completed the study. 75% were taking LABA and daily ICS dose
was 1035 mcg/day (BDP equivalence).
Male and female patients, > 12 years of age, with persistent asthma who were currently
treated with inhaled glucocorticosteroids (IGCSs) and long-acting β2-agonist (LABA)
Interventions Investigational product was Symbicort® Turbuhaler®, 160/4.5 µg/dose budesonide/
formoterol (delivered dose), 1 inhalation b.i.d. as maintenance treatment plus as needed,
in response to symptoms
Comparator products were any conventional best practice treatments, except Symbi-
cort® SMART and/or maintenance with oral glucocorticosteroids prescribed at the dis-
cretion of the investigator according to GINA treatment guidelines Ref: Global Initiative
for Asthma 2002)
Outcomes Primary variable
• Time to first severe asthma exacerbation
Secondary variables
• Total number of severe asthma exacerbations
• Mean use of as needed medication
• Prescribed asthma medications
Patient reported outcomes (PRO)
• Change in Asthma Control Questionnaire (ACQ) score
Safety
Only information regarding SAEs and discontinuations due to AE (DAEs) were collected
in this study
Definition of severe exacerbation
Not specified
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MONO (Continued)
Additional Data
Data on file from AstraZeneca indicated 51/64 patients with at least one course of oral
steroids and 5/7 with at least one hospitalisation on single inhaler therapy/current best
practice (921/914)
Notes One (1) death was reported in the study in the single inhaler therapy group in Denmark.
The patient contacted the investigator 16 August due to asthma deterioration. The
patient discontinued the study and study medication on 9 September 2005 due to
“Subject not willing to continue study” and experienced asthma exacerbation on 30
September 2005. The event was considered serious due to hospitalization, and the patient
died the same day. The events pneumonia and in compensatio cordis lead to death
and not the event of asthma exacerbation. The investigator considered the event to be
unrelated to the study therapy
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No details
Allocation concealment? Unclear No details
Blinding?
All outcomes
No Open study
Incomplete outcome data addressed?
All outcomes
Yes 90% of randomised patients completed the
study and analyses was ITT
NCT00235911
Methods Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy
Study. August 2003 start
Effects of Symbicort Single InhalerTherapy onBronchialHyperResponsiveness, Asthma
Control and Safety in Mild to Moderate Asthmatics in General Practice, Compared
to Usual Care Therapy. The primary objective is to compare the effects of Symbicort
SiT and treatment according to NHG-guidelines on bronchial hyper responsiveness
in asthmatic patients, as measured by PD20 histamine, and to validate the Bronchial
Hyperresponsiveness Questionnaire (BHQ). Two research centres in the Netherlands
Participants Enrolment planned: 100
Inclusion Criteria:
• diagnosis of mild to moderate asthma, FEV1 > 60% of predicted normal values
pre-bronchodilator, daily use of inhaled GCS during the last 3 months
Exclusion Criteria:
• Regular need of >4 inhalations of a short-acting b2-agonist/day, known or
suspected hypersensitivity to any of the investigational drugs or inhaled lactose, use of
any beta-blocking agent, having smoked >10 pack-years
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NCT00235911 (Continued)
Interventions 1. Symbicort SiT
2. Treatment according to NHG-guidelines
Outcomes Primary Outcome Measures:
• Change in PD20 histamine
Secondary Outcome Measures
• Number of asthma-control days
• Time to first mild asthma exacerbation
• Number of mild asthma exacerbation days
• Asthma symptom scores (day and night)
• FEV1
• PEF (morning and evening)
• Number of inhalations with iGCS
• Mean dose of iGCS
Definition of severe exacerbation
Not specified
Additional Data
Data on file from AstraZeneca indicate that no patients were hospitalised, and 2/54
compared to 6/48 patients had at least one course of oral steroids on SMART and current
best practice respectively
Notes Study BN-00S-0011 is reported on the clinical trials register as completed, but no study
report summary had been posted by AstraZeneca on the trials web site (www.astrazeneca-
clinicaltrials.com/ncmprintchapter.aspx?type=article&param=528362) by September
2008
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No details
Allocation concealment? Unclear No details
Blinding?
All outcomes
No Open
Incomplete outcome data addressed?
All outcomes
Unclear No details
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SALTO
Methods This was a randomised, open-label, phase IIIB, multicenter study with a parallel group
design. Patients were treated with either SMART i.e. Symbicort® Turbohaler® 160/
4.5µg/inhalation (delivered dose), 1 inhalation b.i.d. plus as needed (in response to
symptoms), or conventional best practice. The study consisted of the following periods:
2-week run-in period followed by a 26-week randomised treatment period.Usual therapy
used in run-in period
A total of 194 centres in Belgium and Luxembourg participated in this study, between
December 2004 and June 2006
Participants Population: 908 adults and adolescents were randomised. All were analysed for efficacy
and safety and 867 completed the study. 38% classified as moderate persistent asthma,
36% severe persistent asthma and 27% mild persistent asthma. Mean ICS daily dose
during run-in 579 mcg/day (range 100 to 2000).
Inclusion criteria: Male and female, adolescent (≥ 12 years of age) and adult patients
with persistent asthma, currently treated with inhaled glucocorticosteroid (IGCS) or
IGCS and long-acting β2-agonist (LABA)
Interventions 1. Investigation medication was Symbicort® Turbohaler® 160/4.5µg/inhalation
(delivered dose), 1 inhalation b.i.d. + as needed in response to symptoms.
2. Comparators were conventional best practice, active stepwise individualized
treatment according to the Global Initiative for Asthma (GINA) treatment guidelines.
Outcomes Primary variable
• Time to first severe asthma exacerbation
Secondary variables
• Number of severe asthma exacerbations
• Mean use of as-needed medication
• Prescribed asthma medication
• Peak Expiratory Flow (PEF)
Patient-reported outcomes (PROs)
• Asthma Control Questionnaire (ACQ) score
• Satisfaction with Asthma Treatment Questionnaire (SATQ) score
Safety
• SAEs
• Discontinuation due to AE(s)
Definition of severe exacerbation
Not specified
Notes Twenty patients reported a total of 20 serious adverse events during treatment (9 in the
SMART group and 11 in the current best practice group). Six patients discontinued
treatment due to an SAE/AE [4 in the SMART group (including two patients who died
: one suicide and one myocardial infarction with no relation with the treatment) and 2
in the current best practice group]
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No details
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SALTO (Continued)
Allocation concealment? Unclear No details
Blinding?
All outcomes
No Open
Incomplete outcome data addressed?
All outcomes
Unclear No details
Scicchitano 2004
Methods This was a double-blind, double-dummy, randomised, active-controlled, parallel-group,
Multicentre study comparing the efficacy and safety of Symbicort 160/4.5 µg/inhalation,
two inhalations once daily + Symbicort 160/4.5 µg/inhalation as-needed (Symbicort
single-inhaler therapy (SiT)) with Pulmicort 160 µg/inhalation, two inhalations bid
+ Bricanyl 0.4 mg/inhalation as-needed, in adults and adolescents (12-80 years) for a
period of 12 months in the treatment of asthma.(Carried out between May 2001 and
January 2003). The run-in period was on usual ICS dose but LABA was withdrawn
This was a Multicentre study with 211 centres participating from the following 18
countries: Argentina (6 centres), Australia (10 centres), Canada (22 centres), Czech
republic (5 centres), Finland (6 centres), France (29 centres), Germany (20 centres)
, Hungary (7 centres), Israel (17 centres), Italy (11 centres), Mexico (5 centres), the
Netherlands (24 centres), New Zealand (4 centres), Norway (13 centres), Portugal (7
centres), Russia (6 centres), South Africa (11 centres) and Turkey (8 centres)
Participants Population: Mean age: 43 years. FEV1 70% predicted. Mean ICS dose at enrolment
746mcg/day. Hospital admission for asthma in the past year: unknown%. Course of oral
steroids for asthma in past year: unknown%. Previous clinically important exacerbation
required for eligibility. 45% of enrolled patients were already on LABA as well as ICS
Inclusion criteria: Male and female subjects, 12 to 80 years with asthma, previously
treated with inhaled glucocorticosteroids (IGCS) 400-1600 µg per day, with a forced
expiratory volume in one second (FEV1 ) of 50-90% of predicted normal (% P.N. ), a
history of at least one clinical important asthma exacerbation 1-12 months prior to
inclusion, a reversibility in FEV1 from baseline of at least 12%, and who had an asthma
symptom score ≥ 1 during 4 of the last 7 days of the run-in period (in which usual dose
of ICS was used but LABA was withdrawn from the 45% taking LABA previously)
Interventions 1. Budesonide/formoterol 200/6 mcg two inhalation in the evening [400 mcg
budesonide/day], with additional doses as needed as reliever (3 turbuhalers formorning,
evening and relief )
2. Budesonide 200 mcg two inhalations twice daily [800 mcg budesonide/day],
with terbutaline reliever (3 turbuhalers as above with placebo in the morning)
Maximum of 10 as needed inhalations could be used per day before contacting the
investigator
*200/6 mcg actuator dose is described as 160/4.5 mcg delivered dose in the paper
Outcomes Primary efficacy variable
• Severe asthma exacerbations.
• The associated primary efficacy outcome variable was time to first severe asthma
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Scicchitano 2004 (Continued)
exacerbation.
Additional secondary efficacy variables
• The number of severe asthma exacerbations was a secondary outcome variable
• Morning and evening peak expiratory flow (mPEF and ePEF)
• Asthma symptom scores
• Nights with awakening(s) due to asthma symptom
• Inhalations of as-needed medication
• Asthma-control days
• Mild asthma exacerbation days
• As-needed-free days
• Symptom-free days,
FEV1, overall treatment evaluation, and asthmaquality of life questionnaire, standardised
version (AQLQ(S)) overall and domain scores
N.B. As-needed-free days and symptom-free days were added as variables to the statistical
analyses to conform with previous Symbicort studies. It was done after finalisation of
the study protocol, but before un blinding of study data
Safety
Safety assessments including physical examination, adverse events (AEs), pulse and blood
pressure, were obtained in all subjects
Definition of severe exacerbation
Included PEF less than 70% baseline on two consecutive days, severe exacerbations
requiring medical intervention were also reported (hospitalisation, ED visit or course of
oral steroids), but all severe exacerbations were to be treated with a 10 day course of oral
prednisolone
Additional Data
Data on file from AstraZeneca indicated the number patients given at least one course of
oral steroids was129/947 on SMART and 204/943 on Pulmicort. For Hospitalisation/
ER treatment there were 12/947 and 20/947 respectively. Asthma SAE was 5/947 and
11/943 which have been used as the hospital admission outcomes for this study
Notes There were three deaths reported in the study, two in the Pulmicort group and one in
the Symbicort SiT group. None of the deaths were related to asthma or, as judged by
the investigator causally related to investigational
product.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No details
Allocation concealment? Unclear No details
Blinding?
All outcomes
Yes Double blind
Incomplete outcome data addressed?
All outcomes
Yes 1573/1890 completed (83%)
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Methods Randomised, open, parallel group study over a 6 month period. In the two week run-in
patients used current asthma treatment (pre-study ICS +/- LABA). Unknown number
of centres in Canada
Participants Population: 1538 asthmatic adults aged 12 years and over with asthma on at least 400
mcg/day ICS and symptomatic unless also on LABA (74% of those randomised were
on LABA and ICS)
Inclusion Criteria: Aged 12 years or more and asthma diagnosis for a minimum of three
months. Previous treatment with ICS for at least 3 months (at least 400mcg/day) with
at least 3 inhalations of relief medication in the last 7 days of run in, or concurrent use of
LABA. Patients with a smoking history of over 10 pack-years or exacerbation requiring
a change in asthma treatment in the past 14 days were not included; nor were patients
already using Single inhaler Therapy
Baseline Characteristics: Mean age: 40 years. FEV1 not measured but PEF 94%
predicted. Mean ICS dose at enrolment 569 mcg/day, and 74% were also using LABA.
Hospital admission for asthma in the past year:unknown. Course of oral steroids for
asthma in past year: unknown
Interventions 1. Budesonide/formoterol 200/6mcgone inhalation twice daily [400mcg budesonide/
day], as maintenance and reliever
2. Current best practice.
Outcomes Primary outcome:
• Time to first severe exacerbation
Secondary outcomes
• Number of severe exacerbations
• Mean use of as-needed treatment
• Prescribed asthma medications
• PEF
• ACQ. A subgroup used induced sputum eosinophils as a primary outcome.
Definition of severe exacerbation
Hospitalisation, or emergency room visit or course of oral corticosteroids for at least 3
days due to asthma
Notes Study D5890L00004 is reported on the clinical trials register as completed in September
2005, but no study report summary had been posted by AstraZeneca on the trials web
site (http://www.astrazenecaclinicaltrials.com/article/514143.aspx) by September 2008
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No details
Allocation concealment? Unclear No details
Blinding?
All outcomes
No Open
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SOLO (Continued)
Incomplete outcome data addressed?
All outcomes
Yes 1400/1538 (91%) completed the study
Sovani 2008
Methods Randomised, open, parallel group study over a 6 month period
Participants Population: 71 asthmatic adults aged 18-70 years with asthma on at least 400-1000
mcg/day ICS who demonstrated poor compliance and were poorly controlled.
Inclusion Criteria: Aged 18-70 years. Previous treatment with ICS (400-1000 mcg/day
beclometasone equivalent) who demonstrated poor compliance by collecting less than
70% of expected ICS prescriptions in the previous year. Poor control demonstrated by
at least two prescriptions of prednisolone or 10 canisters of reliever inhaler in previous
year. At least four puffs of reliever for at least 4 days per week over past 4 weeks. Patients
with a smoking history of over 20 pack-years or exacerbation requiring oral steroids in
the past 4 weeks were not included
Baseline characteristics: Mean age: 36 years. FEV1 85% predicted. Mean ICS dose at
enrolment 590 mcg/day, but only 278 mcg/day was being taken! Hospital admission
for asthma in the past year: unknown. Course of oral steroids for asthma in past year:
mean of one course per year (SD 1)
Interventions 1. Budesonide/formoterol 200/6 mcg one inhalation twice daily [400 mcg
budesonide/day], as maintenance and reliever.
2. Budesonide 200 mcg [400 mcg budesonide/day], one inhalation twice daily via
Turbohaler and usual reliever
Outcomes Primary outcome:
• Dose of inhaled budesonide.
Secondary outcomes
• FEV1
• MiniAQLQ
• ACQ scores
• Oral corticosteroid use
• Visits to GP for asthma-related problems.
Notes Supported by an unconditional grant from AstraZeneca
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes computer-generated random numbers
Allocation concealment? Yes An independent pharmacist used com-
puter-generated random numbers to ran-
domise each participant to one of two
groups
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Sovani 2008 (Continued)
Blinding?
All outcomes
No Open
Incomplete outcome data addressed?
All outcomes
Yes 55/71 (77%) completed the study and
there were more withdrawals in the control
arm: 13 compared to 3 in active arm (all 3
reported difficulty using the inhaler)
STAY - Adults
Methods Study Design: Randomised, double-blind, parallel group study over a 12 month period
in 246 centres in 22 countries (between Jan 2001 and Jan 2003). In the 14-18 day run-
in patients used pre-study ICS with terbutaline for symptom relief (LABA had to be
discontinued at least 3 days before run-in)
Participants Adult Population: 2419 asthmatic adults aged 12 years or more with asthma uncon-
trolled on ICS (400-1000 mcg/day) and a history of at least one “clinically important”
exacerbation in the past year. The maintenance ICS dose was cut to a quarter with ad-
ditional Formoterol (SiT) or maintenance with Terbutaline for relief
Adults Mean age: 40 years. FEV1 73% predicted pre bronchodilator. Mean ICS dose
at enrolment 660 mcg/day. Hospital admission for asthma in the past year: unknown
proportion. Course of oral steroids for asthma in past year: unknown proportion
Inclusion Criteria: Aged 12-80 years, with a constant dose of ICS (400-1000 mcg/day)
at least 3 months. Prebronchodilator FEV1 of 60-90% predicted normal value and at
least 12% reversibility following Terbutaline. To be included patients had to need at
least 12 rescue inhalations in the last 10 days of run-in. Adults using ten or more rescue
inhalations in a single day or with an exacerbation during run-in were not randomised
Interventions 1. Budesonide/formoterol 100/6 mcg twice daily [200 mcg budesonide/day] and
as needed (one maintenance and one relief Turbuhaler)
2. Budesonide/formoterol 100/6 mcg twice daily [200 mcg budesonide/day] and
Terbutaline as needed (one maintenance and one relief Turbuhaler)
3. Budesonide 400 mcg twice daily [800 mcg budesonide/day] and Terbutaline as
needed (one maintenance and one relief Turbuhaler)
Maximum of 10 as needed inhalations could be used per day before contacting the
investigator
Outcomes Primary outcome
• Time to first severe exacerbations
Secondary outcomes
• Number of severe exacerbations
• Time to mild exacerbations
• Number of mild exacerbations
• Symptom free days
• QOL scores
• No particular variable was chosen to assess safety.
Exacerbation Definition: Severe - Deterioration in asthma requiring hospital or emer-
gency room treatment, or oral steroids (or other additional treatment) or morning PEF
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STAY - Adults (Continued)
70% or less of baseline on two consecutive days. Severe exacerbations requiring med-
ical intervention were analysed separately . Mild exacerbation day - PEF 80% or less
of baseline, relief medication 2 or more inhalations above baseline, or awakenings due
to asthma. Mild exacerbation defined as 2 consecutive mild exacerbation days using the
same criteria
Additional Data
Data on file from AstraZeneca indicate that 7/804 adults and adolescents had at least
one asthma related SAE on SMART and 10/819 on Pulmicort. Similarly 83/804 on
SMART and 149/819 on Pulmicort had at least one course of oral corticosteroids
Notes SAE data (44,46,42) in the adult population; deaths given for whole trial (0,2,1)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated randomisation
scheme
Allocation concealment? Unclear Eligible patients were randomised in bal-
anced blocks by allocating patient numbers
in consecutive order
Blinding?
All outcomes
Yes Double blind. All study medication was
given by turbuhalers. Maintenance and as
needed medication distinguished by the
colour of the label and its wording
Incomplete outcome data addressed?
All outcomes
Yes Withdrawals and Dropouts: 2039/2419
(84%) completed the study
STAY - All ages
Methods see STAY - Adults & STAY - children
Participants Combined data on Children and Adults aged 4 to 60 years with a history of one or more
exacerbations in the past year
Interventions see STAY - Adults & STAY - children
Outcomes see STAY - Adults & STAY - children
Notes Data presented for adults and children. P values based on ANOVA and changes from
baseline calculated from Tables 1 & 2 in the primary publication. Standard Errors esti-
mated from P values
Risk of bias
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STAY - All ages (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Yes See STAY - Adults
Allocation concealment? Unclear See STAY - Adults
Blinding?
All outcomes
Yes See STAY - Adults
Incomplete outcome data addressed?
All outcomes
Yes See STAY - Adults
STAY - Children
Methods Study Design: Randomised, double-blind, parallel group study over a 12 month period
in 41 centres in 12 countries (between Jan 2001 and Jan 2003). In the 14-18 day run-
in patients used pre-study ICS with terbutaline for symptom relief (LABA had to be
discontinued at least 3 days before run-in)
Participants Children in Study: 341 asthmatic children aged 4-11 years with asthma uncontrolled on
ICS (200-500 mcg/day) and a history of at least one “clinically important” exacerbation
in the past year.
Mean age: 8 years. Mean morning PEF: 220 L/min. FEV1 76% predicted pre bron-
chodilator. Mean ICS dose at enrolment 315 mcg/day. Hospital admission for asthma
in the past year: unknown proportion. Course of oral steroids for asthma in past year:
unknown proportion
Inclusion Criteria: Aged 4-11 years, with a constant dose of ICS (200-500 mcg/day) at
least 3months. Prebronchodilator FEV1 of 60-100% predicted normal value and at least
12% reversibility following Terbutaline. To be included patients had to need at least 8
rescue inhalations in the last 10 days of run-in. Children using seven or more rescue
inhalations in a single day or with an exacerbation during run-in were not randomised
Interventions 1. Budesonide 100 mcg (80 mcg delivered dose) and Formoterol 4.5 mcg in the
evening and as needed (one maintenance and one relief Turbuhaler)
2. Budesonide 100 mcg (80 mcg delivered dose) and Formoterol 4.5 mcg in the
evening and Terbutaline as needed (one maintenance and one relief Turbuhaler)
3. Budesonide 400 mcg (320 mcg delivered dose) in the evening and Terbutaline
as needed (one maintenance and one relief Turbuhaler)
Outcomes Primary outcome
• Time to first severe exacerbations
Secondary outcomes
• Number of severe exacerbations
• Time to mild exacerbations
• Number of mild exacerbations
• Symptom free days
• QOL scores
• No particular variable was chosen to assess safety.
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STAY - Children (Continued)
Exacerbation Definition: Severe - Deterioration in asthma requiring hospital or emer-
gency room treatment, or oral steroids (or an increase in ICS or other additional
treatment) or morning PEF 70% or less of baseline on two consecutive days. Severe
exacerbations requiring medical intervention were analysed separately . Mild exac-
erbation day - PEF 80% or less of baseline, relief medication 2 or more inhalations above
baseline, or awakenings due to asthma. Mild exacerbation defined as 2 consecutive mild
exacerbation days using the same criteria
Additional Data
Data on file from AstraZeneca indicate that 0/118 children under the age of 12 years had
at least one asthma related SAE on SMART and 2/106 on Pulmicort. Data on children
given a course of oral corticosteroids has not been obtained
Notes Adverse Events:SAE data given (2,16,5) of these (0,7,2) were related to asthma. Change
from baseline nights with awakenings were the same in both groups, P value in the paper
not used as it related to post treatment levels not changes. No SD data published in
the paper with respect to growth comparing budesonide/formoterol to Terbutaline as
reliever, so SD calculated from the other comparisons presented
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes See STAY - Adults
Allocation concealment? Unclear See STAY - Adults
Blinding?
All outcomes
Yes See STAY - Adults
Incomplete outcome data addressed?
All outcomes
Yes See STAY - Adults
STEAM
Methods The study was double-blind, randomised, active-controlled, multi-centre and multi-
national with a parallel group design comparing the efficacy and safety of Symbicort
80/4.5 µg/inhalation, 2 inhalations once daily plus Symbicort 80/4.5 µg/inhalation as-
needed (Symbicort single-inhaler therapy, SiT)with that of Pulmicort 160 µg/inhalation,
2 inhalations once daily plus Bricanyl 0.4 mg/dose as-needed when given to adults and
adolescents (12-80 years) for a period of 6 months in the treatment of asthma
This was a Multicentre study with 77 centres participating from the following countries:
Argentina (5 centres), Brazil (7 centres), China (4 centres), Denmark (15 centres), In-
donesia (6 centres), Norway (10 centres), The Philippines (10 centres), Spain (9 centres)
, and Sweden (11 centres)
Participants Population: Male and female subjects, 12 to 80 years with asthma, previously treated
with 200-500 µg per day of inhaled glucocorticosteroids (IGCS). They had to have a
forced expiratory volume in one second (FEV1 ) of 60-100% of predicted normal at
Visit 1 and a reversibility in FEV1 from baseline of at least 12% at Visit 1 or 2, or a peak
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STEAM (Continued)
expiratory flow (PEF) variability of at least 12% on at least 3 out of the last 10 days of the
run-in. During the last 10 days of the run-in period the subjects also had to have used at
least 7 inhalations of the as-needed medication. Run-in was on Budesonide 100mcg bd
with Terbutaline prn (this represents around half the previous dose of ICS and LABA
was withdrawn from the 20% participants who were taking LABA previously)
Baseline Characteristics:Mean age: 38 years. FEV1 75% predicted. Mean ICS dose at
enrolment 348 mcg/day and 20% were also on LABA. Hospital admission for asthma
in the past year: unknown. Course of oral steroids for asthma in past year: unknown.
Previous exacerbation not required for eligibility.
Interventions 1. Budesonide/formoterol 100/6 mcg two inhalation in the evening [200 mcg
budesonide/day], with additional doses as needed as reliever
2. Budesonide 200 mcg two inhalations once daily [400 mcg budesonide/day],
with terbutaline reliever
*200 mcg actuator dose is described as 160 mcg delivered dose in the paper
Outcomes Primary outcome:
• Morning PEF.
Secondary outcomes
• Number of severe exacerbations
• FEV1
• Evening PEF
• Asthma symptom score
• As-needed medication
• Nights with awakenings due to asthma
• Asthma-control days
• Number of mild and severe exacerbation days
• As-needed free days
• Symptom-free days were added as outcomes before the data was unblinded.
Exacerbation Definition: Severe - Deterioration in asthma requiring hospital or emer-
gency room treatment, or oral steroids , or at least 30% fall in PEF from baseline on two
consecutive days. If prednisone was needed beyond 10 days this was counted as a second
exacerbation. Mild exacerbation day - defined in other studies as PEF 80% or less of
baseline(average of last 10 days of run-in), relief medication 2 or more inhalations above
baseline, or a night with awakenings due to asthma. No report of definition in trial report
Additional Data
Data on file from AstraZeneca indicate 12/354 patients with at least one course of oral
steroids on SMART and 31/342 on Pulmicort. For asthma-aggravated SAE the figures
were 0/1 and for hospitalisation or ER visits 1/9 (which suggests that most of these were
ER visits as hospitalisation for asthma is a mandatory category for asthma SAE)
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No details
33Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in
adults and children (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
STEAM (Continued)
Allocation concealment? Unclear No details
Blinding?
All outcomes
Yes Double blind
Incomplete outcome data addressed?
All outcomes
Yes 639/697 (92%) completed the study
STYLE
Methods A Comparison of the Efficacy of Symbicort Single Inhaler Therapy (Symbicort Tur-
buhaler® 160/4.5 mcg 1 Inhalation b.i.d. Plus as-Needed) and Conventional Best Prac-
tice for the Treatment of Persistent Asthma in Adolescents and Adults - a 26 Weeks,
Randomised, Open-Label, Parallel-Group, Multicentre Study. July 2005 to December
2006
53 study locations in Chile, Croatia, Czech Republic, Greece, Iceland, Latvia, Lithuania,
Portugal, Slovakia and Slovenia
Participants Age at least 12 years. Aim to enrol 1000 participants.
Inclusion Criteria: - - Diagnosis of asthma at least 3 months - Prescribed daily use of
glucocorticosteroids at a dose > 320 mcg/ day for at least 3 months prior to Visit 1
Exclusion Criteria: - Smoking history > 10 pack-years - Asthma exacerbation requiring
change in asthma treatment during the last 14 days prior to inclusion - Any significant
disease or disorder that may jeopardize the safety of the patient
Interventions The purpose of the study is to compare the efficacy of a flexible dose of Symbicort with
conventional stepwise treatment according to asthma treatment guidelines in patients
with persistent asthma
1. Symbicort Turbuhaler® 160/4.5 mcg 1 Inhalation b.i.d. Plus as-Needed
2. Conventional Best Practice
Outcomes Primary outcome:
• Time to first severe asthma exacerbation
Secondary outcome:
• Number of asthma exacerbations
• Mean use of as-needed medication
• Prescribed asthma medication
• Asthma Control Questionnaire
• Asthma related costs (direct asthma medication, direct non-medication costs and
indirect costs)
Safety: Serious Adverse Events and discontinuations due to adverse eventsAll variables
assessed over the 6 months treatment period
Definition of severe exacerbation
Not specified
Additional Data
Data on file from AstraZeneca indicates no patients with admission for asthma and 43
with at least one course of oral steroids (N=497) on SMART and 3/498 and 56/498
respectively on current best practice
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STYLE (Continued)
Notes This study was completed in December 2006 but no results have yet been published in
medical journals or on the AstraZeneca web site
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No details
Allocation concealment? Unclear No details
Blinding?
All outcomes
No Open
Incomplete outcome data addressed?
All outcomes
Unclear No details
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Balanzat 2004 Overview of three existing trials
Bousquet 2007 Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone
COMPASS Different doses of Symbicort used for maintenance
COSMOS Comparison with maintenance on Fluticasone/Salmeterol
D5890C00003 SiT compared to higher dose maintenance regimen on BDF and Budesonide
Ind 2002 Formoterol v Terbutaline as reliever
Jenkins 2007 budesonide/formoterol dose adjustment with FeNO (not used as reliever)
Jonkers 2006 Single dose study
Loukides 2005 SiT compared to separate inhalers for maintenance treatment and Formoterol relief
Lundborg 2006 Higher dose combination maintenance therapy but no ICS maintenance arm
Richter 2007 Formoterol not combination therapy as reliever
SMILE No comparison with maintenance ICS arm
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SOMA No maintenance ICS arm
Tattersfield 2001 Formoterol v Terbutaline as reliever
Characteristics of ongoing studies [ordered by study ID]
NCT00463866
Trial name or title NCT00463866
Methods The purpose of this study is to evaluate the effect of two different maintenance doses of Symbicort SMART
(Symbicort Maintenance And Reliever Therapy) in adult asthmatic patients. A 6 month treatment period.
Estimated enrolment 8000
Participants Inclusion Criteria:
• Patients at out-patient clinics
• >18 years with a minimum of 6 months documented history of persistent asthma who have used
inhaled glucocorticosteroids for at least one month and have a history of use in rapid-acting B2 agonists for
symptom relief
Exclusion Criteria:
• Asthma exacerbation within the last 14 days prior to study start
• subject aged >40 years with a smoking history of >10pack-years
• subjects with chronic obstructive lung disease or other significant respiratory disease
Interventions Two different doses of SMART therapy - unclear if there is a placebo arm
Outcomes Not described
Starting date March 2007
Contact information
Notes
NCT00628758
Trial name or title NCT00628758
Methods The primary objective is to compare the efficacy of Symbicort Single inhaler Therapywith treatment according
to conventional best practice in adult patients with persistent asthma. Treatment, Randomized, Open Label,
Active Control, Parallel Assignment, Efficacy Study. Estimated enrolment 1000
Participants No details
Interventions A Comparison of Symbicort Single Inhaler Therapy (SymbicortTurbuhaler 160/4.5mcg, 1 Inhalation b.i.d.
Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults a -26-Week,
Randomized, Open-Label, Parallel-Group, Multicentre Study
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NCT00628758 (Continued)
Outcomes PrimaryOutcomeMeasures: Time to first severe asthma exacerbation.Defined deterioration in asthma leading
to at least one of the following:1.Hospitalisation/Emergency room (or equivalent) treatment due to asthma
2.Oral GC treatment due to asthma for at least 3 days
Secondary Outcome Measures: Number of severe asthma exacerbations
Change in AQLQ(S) score from randomisation (visit 1) to Visits 4
Mean use of as-needed medication per day during treatment period
Prescribed asthma medication during the treatment period
Starting date March 2006
Contact information
Notes
SPAIN 2008
Trial name or title Study SPAIN
A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbuhaler 160/4.5 mcg, 1 Inhalation b.i.
d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults - a 26-
Week, Randomised, Open-Label, Parallel-Group, Multicentre Study. Estimated enrolment: 1000
Methods Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Participants Inclusion Criteria:
• Age 18 years or over
• Minimum of 3 months history of asthma, diagnosed according to the American Thoracic Society
(ATS) definition (9).
• Prescribed inhaled GCS at a dose of ?320 µg/day and within the approved label for the relevant drug
during the last 3 months prior to Visit 1.
• Either daily maintenance treatment with both inhaled GCS and long-acting b2-agonist(LABA) or
daily treatment with inhaled GCS alone (i.e. without LABA)
• A history of sub optimal asthma control the month prior to enrolment as judged by the investigator
• Use of at least 3 inhalations of as needed medication for symptom relief during the last 7 days before
enrolment
Exclusion Criteria:
• Previous treatment with Symbicort Single Inhaler;
• Use of any beta-blocking agent, including eye-drops and oral GCS as maintenance treatment.
• Known or suspected hypersensitivity to study therapy or excipients.
• A history of smoking less than 10 pack years.
• Asthma exacerbation requiring change in asthma treatment during the last 14 days prior to or at Visit 1.
Interventions A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbuhaler 160/4.5 mcg, 1 Inhalation b.i.d.
Plus as Needed) and Conventional Best Practice
Outcomes The primary outcome variable will be time to first severe asthma exacerbations. Exacerbations are considered
an appropriate outcome variable by CPMP The definition of a severe asthma exacerbation is based on the
same guideline
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SPAIN 2008 (Continued)
A secondary objective is to collect safety data for treatment in the two treatment groups in adult patients with
persistent asthma
Starting date Sept 2006
Contact information
Notes
SYMPHONIE 2008
Trial name or title SYMPHONIE
Methods A Comparison of Symbicort Single Inhaler and Conventional Best Practice for the Treatment of Persistent
Asthma in Adolescents and Adults. A 26-Week, Randomised, Open, Parallel Group Multicentre Study.
Estimated enrolment: 1000
Participants Inclusion Criteria:
• Age 12 years and older
• Minimum of 3 months history of asthma, diagnosed according to the American Thoracic Society
(ATS) definition. Prescribed inhaled GCS at a dose of ³400 µg/day and within the approved label for the
relevant drug during the last 3 months prior to Visit 1.
Exclusion Criteria:
• Use of any beta-blocking agent, including eye-drops, Use of oral GCS as maintenance treatment, A
history of smoking ³ 10 pack years (1 pack year = 1 pack (20 cigarettes) per day for one year or equivalent).
Interventions A flexible dose of Symbicort compared with conventional stepwise treatment according to asthma treatment
guidelines in patients with persistent asthma
Outcomes Primary Outcome Measures: Time to first severe asthma exacerbation
Secondary Outcome Measures: Number of asthma exacerbations, Mean use of as-needed medication, Pre-
scribed asthma medication, Asthma Control Questionnaire, Satisfaction with Asthma Treatment Question-
naire, Safety: Serious Adverse Events and discontinuations due to adverse events
Starting date Sept 2005
Contact information
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Adults and Adolescents treated with Single Inhaler Therapy versus Current Best Practice
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Patients with exacerbations
causing hospitalisation
5 5378 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.59 [0.24, 1.45]
2 Patients with exacerbations
treated with oral steroids
4 4470 Odds Ratio (M-H, Fixed, 95% CI) 0.83 [0.66, 1.03]
3 Serious Adverse Events (fatal) 3 4281 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.95 [0.39, 9.67]
4 Serious Adverse Events
(non-fatal)
3 4281 Odds Ratio (M-H, Fixed, 95% CI) 1.02 [0.68, 1.52]
5 Discontinuation due to Adverse
Events
3 4281 Odds Ratio (M-H, Fixed, 95% CI) 2.92 [1.70, 5.01]
6 Patients with “severe”
exacerbation (time to event)
3 4281 Hazard Ratio (Fixed, 95% CI) 0.96 [0.85, 1.07]
7 Change in PEF (% predicted) 1 Mean Difference (Fixed, 95% CI) Subtotals only
8 Rescue Medication Use (puffs
per day)
1 Mean Difference (Fixed, 95% CI) Subtotals only
9 Quality of Life (Change in ACQ
score)
2 Mean Difference (Fixed, 95% CI) Totals not selected
10 ICS dose (micrograms per day) 3 Mean Difference (Fixed, 95% CI) Totals not selected
Comparison 2. Adults and Adolescents treated with Single Inhaler Therapy versus fixed dose ICS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Patients with exacerbations
causing hospitalisation
3 4209 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.56 [0.28, 1.09]
1.1 Single inhaler therapy
versus higher dose ICS
3 4209 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.56 [0.28, 1.09]
2 Patients with exacerbations
treated with oral steroids
4 4280 Odds Ratio (M-H, Fixed, 95% CI) 0.54 [0.45, 0.64]
2.1 Single inhaler therapy
versus higher dose ICS
3 4209 Odds Ratio (M-H, Fixed, 95% CI) 0.53 [0.44, 0.63]
2.2 Single inhaler therapy
versus same dose ICS
1 71 Odds Ratio (M-H, Fixed, 95% CI) 1.42 [0.29, 6.86]
3 Serious Adverse Events (fatal) 3 4209 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.37 [0.05, 2.62]
3.1 Single inhaler therapy
versus higher dose ICS
3 4209 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.37 [0.05, 2.62]
4 Serious Adverse Events
(non-fatal)
3 4209 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.73, 1.29]
4.1 Single inhaler therapy
versus higher dose ICS
3 4209 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.73, 1.29]
39Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in
adults and children (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
5 Discontinuation due to Adverse
Events
2 2586 Odds Ratio (M-H, Fixed, 95% CI) 0.57 [0.35, 0.93]
5.1 Single inhaler therapy
versus higher dose ICS
2 2586 Odds Ratio (M-H, Fixed, 95% CI) 0.57 [0.35, 0.93]
6 Patients with “severe”
exacerbation (time to event)
2 2586 Hazard Ratio (Fixed, 95% CI) 0.59 [0.49, 0.70]
6.1 Single inhaler therapy
versus higher dose ICS
2 2586 Hazard Ratio (Fixed, 95% CI) 0.59 [0.49, 0.70]
7 PEF (Litres/min) 3 Mean Difference (Fixed, 95% CI) 22.29 [17.62, 26.95]
7.1 Single inhaler therapy
versus higher dose ICS
3 Mean Difference (Fixed, 95% CI) 22.29 [17.62, 26.95]
8 FEV1 increase (Litres) 3 Mean Difference (Fixed, 95% CI) 0.10 [0.07, 0.13]
8.1 Single inhaler therapy
versus higher dose ICS
2 Mean Difference (Fixed, 95% CI) 0.10 [0.08, 0.13]
8.2 Single inhaler therapy
versus same dose ICS
1 Mean Difference (Fixed, 95% CI) 0.01 [-0.19, 0.21]
9 Rescue Medication Use (puffs
per day)
3 Mean Difference (Fixed, 95% CI) -0.37 [-0.49, -0.25]
9.1 Single inhaler therapy
versus higher dose ICS
3 Mean Difference (Fixed, 95% CI) -0.37 [-0.49, -0.25]
10 Quality of Life (Fall in ACQ
score)
1 Mean Difference (Fixed, 95% CI) 0.15 [-0.46, 0.76]
10.1 Single inhaler therapy
versus same dose ICS
1 Mean Difference (Fixed, 95% CI) 0.15 [-0.46, 0.76]
Comparison 3. Children treated with Single Inhaler Therapy versus higher fixed dose ICS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Patients with exacerbations
causing hospitalisation
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
2 Serious Adverse Events (fatal) 1 224 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
3 Serious Adverse Events
(non-fatal)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Annual Height gain (cms) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Children with low plasma
cortisol (<400 nmol/L)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Patients with an exacerbation
requiring increase in ICS or
other treatment
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Change in morning PEF (L/min) 1 Mean Difference (Fixed, 95% CI) Totals not selected
8 Change in clinic FEV1(Litres) 1 Mean Difference (Fixed, 95% CI) Totals not selected
9 As needed medication use over
24 hours
1 Mean Difference (Fixed, 95% CI) Totals not selected
10 Nocturnal awakenings 1 Mean Difference (Fixed, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 Adults and Adolescents treated with Single Inhaler Therapy versus Current
Best Practice, Outcome 1 Patients with exacerbations causing hospitalisation.
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 1 Adults and Adolescents treated with Single Inhaler Therapy versus Current Best Practice
Outcome: 1 Patients with exacerbations causing hospitalisation
Study or subgroup Single inhaler therapy
Current
best
practice
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
MONO 5/921 7/914 0.71 [ 0.23, 2.21 ]
NCT00235911 0/54 0/48 0.0 [ 0.0, 0.0 ]
SALTO 2/450 1/458 1.99 [ 0.21, 19.14 ]
SOLO 0/772 1/766 0.13 [ 0.00, 6.77 ]
STYLE 0/497 3/498 0.14 [ 0.01, 1.30 ]
Total (95% CI) 2694 2684 0.59 [ 0.24, 1.45 ]
Total events: 7 (Single inhaler therapy), 12 (Current best practice)
Heterogeneity: Chi2 = 3.38, df = 3 (P = 0.34); I2 =11%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 1.2. Comparison 1 Adults and Adolescents treated with Single Inhaler Therapy versus Current
Best Practice, Outcome 2 Patients with exacerbations treated with oral steroids.
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 1 Adults and Adolescents treated with Single Inhaler Therapy versus Current Best Practice
Outcome: 2 Patients with exacerbations treated with oral steroids
Study or subgroup Single inhaler therapy
Current
best
practice Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
MONO 51/921 64/914 35.9 % 0.78 [ 0.53, 1.14 ]
NCT00235911 2/54 6/48 3.6 % 0.27 [ 0.05, 1.40 ]
SOLO 57/772 55/766 30.3 % 1.03 [ 0.70, 1.51 ]
STYLE 43/497 56/498 30.2 % 0.75 [ 0.49, 1.14 ]
Total (95% CI) 2244 2226 100.0 % 0.83 [ 0.66, 1.03 ]
Total events: 153 (Single inhaler therapy), 181 (Current best practice)
Heterogeneity: Chi2 = 3.35, df = 3 (P = 0.34); I2 =11%
Test for overall effect: Z = 1.66 (P = 0.096)
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Analysis 1.3. Comparison 1 Adults and Adolescents treated with Single Inhaler Therapy versus Current
Best Practice, Outcome 3 Serious Adverse Events (fatal).
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 1 Adults and Adolescents treated with Single Inhaler Therapy versus Current Best Practice
Outcome: 3 Serious Adverse Events (fatal)
Study or subgroup Single inhaler therapy
Current
best
practice
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
MONO 1/921 0/914 16.7 % 7.33 [ 0.15, 369.58 ]
SALTO 2/450 0/458 33.3 % 7.54 [ 0.47, 120.72 ]
SOLO 1/772 2/766 50.0 % 0.51 [ 0.05, 4.90 ]
Total (95% CI) 2143 2138 100.0 % 1.95 [ 0.39, 9.67 ]
Total events: 4 (Single inhaler therapy), 2 (Current best practice)
Heterogeneity: Chi2 = 2.70, df = 2 (P = 0.26); I2 =26%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Adults and Adolescents treated with Single Inhaler Therapy versus Current
Best Practice, Outcome 4 Serious Adverse Events (non-fatal).
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 1 Adults and Adolescents treated with Single Inhaler Therapy versus Current Best Practice
Outcome: 4 Serious Adverse Events (non-fatal)
Study or subgroup Single inhaler therapy
Current
best
practice Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
MONO 25/921 25/914 51.0 % 0.99 [ 0.57, 1.74 ]
SALTO 9/450 11/458 22.3 % 0.83 [ 0.34, 2.02 ]
SOLO 16/772 13/766 26.7 % 1.23 [ 0.59, 2.57 ]
Total (95% CI) 2143 2138 100.0 % 1.02 [ 0.68, 1.52 ]
Total events: 50 (Single inhaler therapy), 49 (Current best practice)
Heterogeneity: Chi2 = 0.45, df = 2 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Adults and Adolescents treated with Single Inhaler Therapy versus Current
Best Practice, Outcome 5 Discontinuation due to Adverse Events.
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 1 Adults and Adolescents treated with Single Inhaler Therapy versus Current Best Practice
Outcome: 5 Discontinuation due to Adverse Events
Study or subgroup Single inhaler therapy
Current
best
practice Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
MONO 21/921 9/914 50.2 % 2.35 [ 1.07, 5.15 ]
SALTO 4/450 2/458 11.2 % 2.04 [ 0.37, 11.22 ]
SOLO 27/772 7/766 38.6 % 3.93 [ 1.70, 9.08 ]
Total (95% CI) 2143 2138 100.0 % 2.92 [ 1.70, 5.01 ]
Total events: 52 (Single inhaler therapy), 18 (Current best practice)
Heterogeneity: Chi2 = 0.95, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 3.90 (P = 0.000097)
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Analysis 1.6. Comparison 1 Adults and Adolescents treated with Single Inhaler Therapy versus Current
Best Practice, Outcome 6 Patients with “severe” exacerbation (time to event).
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 1 Adults and Adolescents treated with Single Inhaler Therapy versus Current Best Practice
Outcome: 6 Patients with ”severe” exacerbation (time to event)
Study or subgroup Single inhaler therapy
Current
best
practice log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
MONO 921 914 -0.2357 (0.18) 10.6 % 0.79 [ 0.56, 1.12 ]
SALTO 450 458 -0.0212 (0.066) 78.8 % 0.98 [ 0.86, 1.11 ]
SOLO 772 766 -0.01005 (0.18) 10.6 % 0.99 [ 0.70, 1.41 ]
Total (95% CI) 100.0 % 0.96 [ 0.85, 1.07 ]
Heterogeneity: Chi2 = 1.29, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Adults and Adolescents treated with Single Inhaler Therapy versus Current
Best Practice, Outcome 7 Change in PEF (% predicted).
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 1 Adults and Adolescents treated with Single Inhaler Therapy versus Current Best Practice
Outcome: 7 Change in PEF (% predicted)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
SOLO 1 (1) 1.00 [ -0.96, 2.96 ]
Subtotal (95% CI) 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Adults and Adolescents treated with Single Inhaler Therapy versus Current
Best Practice, Outcome 8 Rescue Medication Use (puffs per day).
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 1 Adults and Adolescents treated with Single Inhaler Therapy versus Current Best Practice
Outcome: 8 Rescue Medication Use (puffs per day)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
SOLO -0.158 (0.055) -0.16 [ -0.27, -0.05 ]
Subtotal (95% CI) 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Adults and Adolescents treated with Single Inhaler Therapy versus Current
Best Practice, Outcome 9 Quality of Life (Change in ACQ score).
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 1 Adults and Adolescents treated with Single Inhaler Therapy versus Current Best Practice
Outcome: 9 Quality of Life (Change in ACQ score)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
SALTO -0.13 (0.043) -0.13 [ -0.21, -0.05 ]
SOLO 0.04 (0.054) 0.04 [ -0.07, 0.15 ]
-0.1 -0.05 0 0.05 0.1
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Analysis 1.10. Comparison 1 Adults and Adolescents treated with Single Inhaler Therapy versus Current
Best Practice, Outcome 10 ICS dose (micrograms per day).
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 1 Adults and Adolescents treated with Single Inhaler Therapy versus Current Best Practice
Outcome: 10 ICS dose (micrograms per day)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
MONO -188 (44) -188.00 [ -274.24, -101.76 ]
SALTO -107 (26) -107.00 [ -157.96, -56.04 ]
SOLO -267 (21) -267.00 [ -308.16, -225.84 ]
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Analysis 2.1. Comparison 2 Adults and Adolescents treated with Single Inhaler Therapy versus fixed dose
ICS, Outcome 1 Patients with exacerbations causing hospitalisation.
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 2 Adults and Adolescents treated with Single Inhaler Therapy versus fixed dose ICS
Outcome: 1 Patients with exacerbations causing hospitalisation
Study or subgroup Single inhaler therapy ICS maintenance
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Single inhaler therapy versus higher dose ICS
Scicchitano 2004 5/947 11/943 47.1 % 0.47 [ 0.17, 1.25 ]
STAY - Adults 7/804 10/819 49.9 % 0.71 [ 0.27, 1.85 ]
STEAM 0/354 1/342 3.0 % 0.13 [ 0.00, 6.59 ]
Total (95% CI) 2105 2104 100.0 % 0.56 [ 0.28, 1.09 ]
Total events: 12 (Single inhaler therapy), 22 (ICS maintenance)
Heterogeneity: Chi2 = 0.90, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.088)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Adults and Adolescents treated with Single Inhaler Therapy versus fixed dose
ICS, Outcome 2 Patients with exacerbations treated with oral steroids.
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 2 Adults and Adolescents treated with Single Inhaler Therapy versus fixed dose ICS
Outcome: 2 Patients with exacerbations treated with oral steroids
Study or subgroup Single inhaler therapy ICS maintenance Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Single inhaler therapy versus higher dose ICS
Scicchitano 2004 129/947 204/943 51.6 % 0.57 [ 0.45, 0.73 ]
STAY - Adults 83/804 149/819 38.7 % 0.52 [ 0.39, 0.69 ]
STEAM 12/354 31/342 8.9 % 0.35 [ 0.18, 0.70 ]
Subtotal (95% CI) 2105 2104 99.2 % 0.53 [ 0.44, 0.63 ]
Total events: 224 (Single inhaler therapy), 384 (ICS maintenance)
Heterogeneity: Chi2 = 1.77, df = 2 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 6.96 (P < 0.00001)
2 Single inhaler therapy versus same dose ICS
Sovani 2008 4/35 3/36 0.8 % 1.42 [ 0.29, 6.86 ]
Subtotal (95% CI) 35 36 0.8 % 1.42 [ 0.29, 6.86 ]
Total events: 4 (Single inhaler therapy), 3 (ICS maintenance)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
Total (95% CI) 2140 2140 100.0 % 0.54 [ 0.45, 0.64 ]
Total events: 228 (Single inhaler therapy), 387 (ICS maintenance)
Heterogeneity: Chi2 = 3.24, df = 3 (P = 0.36); I2 =7%
Test for overall effect: Z = 6.87 (P < 0.00001)
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Analysis 2.3. Comparison 2 Adults and Adolescents treated with Single Inhaler Therapy versus fixed dose
ICS, Outcome 3 Serious Adverse Events (fatal).
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 2 Adults and Adolescents treated with Single Inhaler Therapy versus fixed dose ICS
Outcome: 3 Serious Adverse Events (fatal)
Study or subgroup Single inhaler therapy ICS maintenance
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Single inhaler therapy versus higher dose ICS
Scicchitano 2004 1/947 2/943 0.51 [ 0.05, 4.92 ]
STAY - Adults 0/804 1/819 0.14 [ 0.00, 6.95 ]
STEAM 0/354 0/342 0.0 [ 0.0, 0.0 ]
Total (95% CI) 2105 2104 0.37 [ 0.05, 2.62 ]
Total events: 1 (Single inhaler therapy), 3 (ICS maintenance)
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Adults and Adolescents treated with Single Inhaler Therapy versus fixed dose
ICS, Outcome 4 Serious Adverse Events (non-fatal).
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 2 Adults and Adolescents treated with Single Inhaler Therapy versus fixed dose ICS
Outcome: 4 Serious Adverse Events (non-fatal)
Study or subgroup Single inhaler therapy ICS maintenance Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Single inhaler therapy versus higher dose ICS
Scicchitano 2004 49/947 50/943 49.2 % 0.97 [ 0.65, 1.46 ]
STAY - Adults 44/804 46/819 44.6 % 0.97 [ 0.64, 1.49 ]
STEAM 6/354 6/342 6.2 % 0.97 [ 0.31, 3.02 ]
Total (95% CI) 2105 2104 100.0 % 0.97 [ 0.73, 1.29 ]
Total events: 99 (Single inhaler therapy), 102 (ICS maintenance)
Heterogeneity: Chi2 = 0.00, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Adults and Adolescents treated with Single Inhaler Therapy versus fixed dose
ICS, Outcome 5 Discontinuation due to Adverse Events.
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 2 Adults and Adolescents treated with Single Inhaler Therapy versus fixed dose ICS
Outcome: 5 Discontinuation due to Adverse Events
Study or subgroup Single inhaler therapy ICS maintenance Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Single inhaler therapy versus higher dose ICS
Scicchitano 2004 24/947 38/943 82.1 % 0.62 [ 0.37, 1.04 ]
STEAM 3/354 8/342 17.9 % 0.36 [ 0.09, 1.36 ]
Total (95% CI) 1301 1285 100.0 % 0.57 [ 0.35, 0.93 ]
Total events: 27 (Single inhaler therapy), 46 (ICS maintenance)
Heterogeneity: Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 2.27 (P = 0.023)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Adults and Adolescents treated with Single Inhaler Therapy versus fixed dose
ICS, Outcome 6 Patients with “severe” exacerbation (time to event).
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 2 Adults and Adolescents treated with Single Inhaler Therapy versus fixed dose ICS
Outcome: 6 Patients with ”severe” exacerbation (time to event)
Study or subgroup Single inhaler therapy ICS maintenance log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Single inhaler therapy versus higher dose ICS
Scicchitano 2004 947 943 -0.4943 (0.098) 85.5 % 0.61 [ 0.50, 0.74 ]
STEAM 354 342 -0.7765 (0.238) 14.5 % 0.46 [ 0.29, 0.73 ]
Total (95% CI) 100.0 % 0.59 [ 0.49, 0.70 ]
Heterogeneity: Chi2 = 1.20, df = 1 (P = 0.27); I2 =17%
Test for overall effect: Z = 5.91 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Adults and Adolescents treated with Single Inhaler Therapy versus fixed dose
ICS, Outcome 7 PEF (Litres/min).
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 2 Adults and Adolescents treated with Single Inhaler Therapy versus fixed dose ICS
Outcome: 7 PEF (Litres/min)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Single inhaler therapy versus higher dose ICS
Scicchitano 2004 20.3 (6.3) 14.3 % 20.30 [ 7.95, 32.65 ]
STAY - Adults 16 (5) 22.7 % 16.00 [ 6.20, 25.80 ]
STEAM 25 (3) 63.0 % 25.00 [ 19.12, 30.88 ]
Total (95% CI) 100.0 % 22.29 [ 17.62, 26.95 ]
Heterogeneity: Chi2 = 2.50, df = 2 (P = 0.29); I2 =20%
Test for overall effect: Z = 9.36 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Adults and Adolescents treated with Single Inhaler Therapy versus fixed dose
ICS, Outcome 8 FEV1 increase (Litres).
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 2 Adults and Adolescents treated with Single Inhaler Therapy versus fixed dose ICS
Outcome: 8 FEV1 increase (Litres)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Single inhaler therapy versus higher dose ICS
Scicchitano 2004 0.1 (0.015) 78.6 % 0.10 [ 0.07, 0.13 ]
STAY - Adults 0.11 (0.03) 19.6 % 0.11 [ 0.05, 0.17 ]
Subtotal (95% CI) 98.2 % 0.10 [ 0.08, 0.13 ]
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 7.60 (P < 0.00001)
2 Single inhaler therapy versus same dose ICS
Sovani 2008 0.01 (0.1) 1.8 % 0.01 [ -0.19, 0.21 ]
Subtotal (95% CI) 1.8 % 0.01 [ -0.19, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
Total (95% CI) 100.0 % 0.10 [ 0.07, 0.13 ]
Heterogeneity: Chi2 = 0.92, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 7.55 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.83, df = 1 (P = 0.36), I2 =0.0%
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Analysis 2.9. Comparison 2 Adults and Adolescents treated with Single Inhaler Therapy versus fixed dose
ICS, Outcome 9 Rescue Medication Use (puffs per day).
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 2 Adults and Adolescents treated with Single Inhaler Therapy versus fixed dose ICS
Outcome: 9 Rescue Medication Use (puffs per day)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Single inhaler therapy versus higher dose ICS
Scicchitano 2004 -0.52 (0.16) 15.0 % -0.52 [ -0.83, -0.21 ]
STAY - Adults -0.35 (0.11) 31.8 % -0.35 [ -0.57, -0.13 ]
STEAM -0.34 (0.085) 53.2 % -0.34 [ -0.51, -0.17 ]
Total (95% CI) 100.0 % -0.37 [ -0.49, -0.25 ]
Heterogeneity: Chi2 = 1.04, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 5.97 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.10. Comparison 2 Adults and Adolescents treated with Single Inhaler Therapy versus fixed dose
ICS, Outcome 10 Quality of Life (Fall in ACQ score).
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 2 Adults and Adolescents treated with Single Inhaler Therapy versus fixed dose ICS
Outcome: 10 Quality of Life (Fall in ACQ score)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Single inhaler therapy versus same dose ICS
Sovani 2008 0.15 (0.31) 100.0 % 0.15 [ -0.46, 0.76 ]
Total (95% CI) 100.0 % 0.15 [ -0.46, 0.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Children treated with Single Inhaler Therapy versus higher fixed dose ICS,
Outcome 1 Patients with exacerbations causing hospitalisation.
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 3 Children treated with Single Inhaler Therapy versus higher fixed dose ICS
Outcome: 1 Patients with exacerbations causing hospitalisation
Study or subgroup Single inhaler therapy ICS maintenance
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
STAY - Children 0/118 1/107 0.12 [ 0.00, 6.18 ]
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Analysis 3.2. Comparison 3 Children treated with Single Inhaler Therapy versus higher fixed dose ICS,
Outcome 2 Serious Adverse Events (fatal).
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 3 Children treated with Single Inhaler Therapy versus higher fixed dose ICS
Outcome: 2 Serious Adverse Events (fatal)
Study or subgroup Single inhaler therapy ICS maintenance Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
STAY - Children 0/118 0/106 0.0 [ 0.0, 0.0 ]
Total (95% CI) 118 106 0.0 [ 0.0, 0.0 ]
Total events: 0 (Single inhaler therapy), 0 (ICS maintenance)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Children treated with Single Inhaler Therapy versus higher fixed dose ICS,
Outcome 3 Serious Adverse Events (non-fatal).
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 3 Children treated with Single Inhaler Therapy versus higher fixed dose ICS
Outcome: 3 Serious Adverse Events (non-fatal)
Study or subgroup Single inhaler therapy ICS maintenance Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
STAY - Children 2/118 5/106 0.35 [ 0.07, 1.83 ]
0.01 0.1 1 10 100
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Analysis 3.4. Comparison 3 Children treated with Single Inhaler Therapy versus higher fixed dose ICS,
Outcome 4 Annual Height gain (cms).
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 3 Children treated with Single Inhaler Therapy versus higher fixed dose ICS
Outcome: 4 Annual Height gain (cms)
Study or subgroup Single inhaler therapy ICS maintenance
Mean
Difference
Mean
Difference
N Mean(SD)[cm/year] N Mean(SD)[cm/year] IV,Fixed,95% CI IV,Fixed,95% CI
STAY - Children 118 5.3 (2.7) 106 4.3 (2.7) 1.00 [ 0.29, 1.71 ]
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Analysis 3.5. Comparison 3 Children treated with Single Inhaler Therapy versus higher fixed dose ICS,
Outcome 5 Children with low plasma cortisol (<400 nmol/L).
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 3 Children treated with Single Inhaler Therapy versus higher fixed dose ICS
Outcome: 5 Children with low plasma cortisol (<400 nmol/L)
Study or subgroup Single inhaler therapy ICS maintenance Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
STAY - Children 2/51 3/41 0.52 [ 0.08, 3.25 ]
0.01 0.1 1 10 100
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Analysis 3.6. Comparison 3 Children treated with Single Inhaler Therapy versus higher fixed dose ICS,
Outcome 6 Patients with an exacerbation requiring increase in ICS or other treatment.
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 3 Children treated with Single Inhaler Therapy versus higher fixed dose ICS
Outcome: 6 Patients with an exacerbation requiring increase in ICS or other treatment
Study or subgroup Single inhaler therapy ICS maintenance Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
STAY - Children 9/118 21/106 0.33 [ 0.15, 0.77 ]
0.2 0.5 1 2 5
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Analysis 3.7. Comparison 3 Children treated with Single Inhaler Therapy versus higher fixed dose ICS,
Outcome 7 Change in morning PEF (L/min).
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 3 Children treated with Single Inhaler Therapy versus higher fixed dose ICS
Outcome: 7 Change in morning PEF (L/min)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
STAY - Children 12 (3.8) 12.00 [ 4.55, 19.45 ]
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Analysis 3.8. Comparison 3 Children treated with Single Inhaler Therapy versus higher fixed dose ICS,
Outcome 8 Change in clinic FEV1(Litres).
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 3 Children treated with Single Inhaler Therapy versus higher fixed dose ICS
Outcome: 8 Change in clinic FEV1(Litres)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
STAY - Children 0.1 (0.12) 0.10 [ -0.14, 0.34 ]
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Analysis 3.9. Comparison 3 Children treated with Single Inhaler Therapy versus higher fixed dose ICS,
Outcome 9 As needed medication use over 24 hours.
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 3 Children treated with Single Inhaler Therapy versus higher fixed dose ICS
Outcome: 9 As needed medication use over 24 hours
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
STAY - Children -0.2 (0.12) -0.20 [ -0.44, 0.04 ]
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Analysis 3.10. Comparison 3 Children treated with Single Inhaler Therapy versus higher fixed dose ICS,
Outcome 10 Nocturnal awakenings.
Review: Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Comparison: 3 Children treated with Single Inhaler Therapy versus higher fixed dose ICS
Outcome: 10 Nocturnal awakenings
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
STAY - Children -2 (0.68) -2.00 [ -3.33, -0.67 ]
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Date Event Description
11 November 2009 Amended Typological errors corrected (doses corrected to mcg not mg). The Sovani study was designed to
assess compliance with inhaled (not oral) corticosteroids
H I S T O R Y
Protocol first published: Issue 3, 2008
Review first published: Issue 2, 2009
C O N T R I B U T I O N S O F A U T H O R S
Chris Cates and Toby Lasserson conceived of the idea for this review, wrote the protocol, assessed the studies for inclusion, extracted
the data from the papers and web reports and co-wrote the review.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
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External sources
• NHS Cochrane Collaboration Programme Grant Scheme, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This review has been focused on formoterol and budesonide as maintenance and reliever therapy, rather than formoterol with any
inhaled corticosteroid. Steroid load and discontinuation due to adverse events were post hoc outcomes, added after the protocol. When
zero cells were present for an outcome in any of the included studies the Peto Odds Ratio was used to combine the results, as it does
not require a continuity correction to be used.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Inhalation; AdrenalCortexHormones [∗ administration&dosage]; Anti-Asthmatic Agents [∗ administration&dosage];
Asthma [∗drug therapy]; Bronchodilator Agents [administration & dosage]; Budesonide [∗administration & dosage]; Chronic Disease;
Drug Therapy, Combination; Ethanolamines [∗administration & dosage]; Terbutaline [administration & dosage]
MeSH check words
Adult; Child; Humans
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